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Abstract
The response of tumor intracellular pH to a pharmacological challenge could help identify
aggressive cancer. pHi is important in the maintenance of normal cell function and is normally
maintained within a narrow range by the activity of transporters located at the plasma membrane.
Modulation of tumor pHi may influence proliferation, apoptosis, chemotherapy resistance, and
thermosensitivity. Chemical exchange saturation transfer (CEST) is a novel MRI contrast
mechanism that is dependent on cellular pH. Amine and amide concentration-independent
detection (AACID) is a recently developed CEST contrast method that is intracellular pH (pHi)
weighted.
The overall goal of this thesis was to maximize the magnitude of intracellular tumor acidification
using pharmacologic agents. To this end, a series of studies were performed to quantify the
magnitude of acute pHi change in glioblastoma after the injection of a single dose of drugs
known to interfere with pH regulation. In addition, we attempted to simulatenously block five
pH regulatory mechanisms while also providing glucose as an energy substrate to maximize
tumor acidification. We hypothesized that this approach would increase the acute pH
modulation effect. Using a 9.4T MRI scanner CEST spectra were acquired sensitive to pHi using
amine / amide concentration independen detection (AACID).
For these experiments a number of different drugs were utilized. Dichloroacetate (DCA) can
alter tumor pHi by inhibiting the enzyme pyruvate dehydrogenase kinase causing reduced lactate
(increasing pHi), or by decreasing the expression of monocarboxylate transporters and vacuolar
ATPase leading to reduced pHi in tumors. The sodium proton exchanger (NHE1) plays a
significant role in maintaining pH balance in the tumor microenvironment. Cariporide is a
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sodium proton exchange inhibitor and has been shown to suppress the invasion and migration of
cancer cells. Quercetin is an inhibitor of monocarboxylate transporters (MCTs). It specifically
inhibits MCT1 and MCT2. Pantoprazole is a proton pump inhibitor (PPI) that targets the
vacuolar H+-ATPase and has been shown to decrease intracellular pH and increase apoptotic cell
death in cancer cells. Finally, acetazolamide inhibits carbonic anhydrase activity and decreases
expression of the aquaporin-1 (AQP1) water channel.
In the first study, one hour after DCA intravenous injection (200 mg/kg) there was a significant
increase in tumor AACID level by 0.04±0.01 corresponding to a 0.16 decrease in pHi, and no
change in AACID in contralateral tissue. In a second study, two hours after cariporide
intraperitoneal injection there was a significant 0.12±0.03 increase in tumor AACID value
corresponding to a 0.48 decrease in pHi, and no change in AACID value in contralateral tissue.
In a final study, two hours after combined intraperitoneal injection of all five drugs, there was a
significant 0.10±0.03 increase in tumor AACID corresponding to a 0.40 decrease in pHi. After
injecting the drug combination with glucose the AACID value increased by 0.18±0.03
corresponding to a 0.72 decrease in pHi. AACID values were unchanged in contralateral tissue.
The combined drug treatment with glucose produced the largest acute CEST MRI contrast
indicating tumor acidification. This approach could be used to help localize brain cancer and
monitor tumor response to chemotherapy. The use of the approved drugs in combination with pH
weighted MRI represents a unique approach to cancer detection does not require injection of an
imaging contrast agent.
Keywords: Brain cancer; Glioblastoma multiforme(GBM); Apoptosis; pH; MRI; CEST
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Chapter 1
1 Endogenous Magnetic Resonance Imaging and Spectroscopy
Measurements of Intracellular pH in Cancer

Abstract:
Intracellular pH (pHi) plays an important role in the maintenance of normal cell function
and is maintained within a narrow range by the activity of transporters located at the plasma
membrane. A common characteristic of cancer cells is their increased production of acidic
metabolites and consequently, enhanced acid export to the extracellular space. As a result, cancer
cells have relatively basic intracellular pH compared to normal cells. The consequent
acidification of the extracellular tumor microenvironment supports tumor growth and increases
metastatic potential. Tumor intracellular pH is an informative indicator of the tumor
microenvironment as many proteins and peptides have pH-dependent structures and activities.
In addition, manipulation of tumor pHi can influence proliferation, apoptosis, chemotherapy
resistance, and thermosensitivity. Therefore, accurate measurement of tumor intracellular pH
could have many potential applications. The current review summarizes recent advances in
endogenous MRI methods to measure tumor intracellular pH and summarizes studies that use
drug treatments to manipulate intracellular pH in cancer.
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1. Introduction
Elevated intracellular pH in cancer is regulated by several mechanisms that can be
simultaneously blocked by a combination of drugs leading to acute intracellular acidification.
The work presented in this thesis applies a technique called chemical exchange saturation
transfer (CEST) magnetic resonance imaging (MRI) to study intracellular acidification in brain
tumors after drug injection.
This chapter provides an introduction and outline to the presented research on
intracellular pH measurement in cancer and the drugs that can modulate intracellular pH in
tumors. Section 1.1 outlines the general organization of the thesis. The regulation of pH in
normal cells and in cancer cells is presented in Section 1.2. An introduction to CEST theory and
mechanisms of producing MRI contrast is presented in Section 1.3. Endogenous MRI
measurement of intracellular pH presented in Section 1.4. Endogenous MRI measurement of
intracellular pH in cancer is presented in Section 1.5. Finally, a description of various drugs that
can be used to modulate pH in cancer is presented in Section 1.6.

1.1 Thesis Overview and Objectives

Anatomical MRI can provide valuable clinical information and enable diagnosis (1-3) in
many diseases including cancer. MRI can produce excellent soft-tissue contrast with highresolution that allows localization and differentiation between different types of soft tissue.
Advances in the understanding of cell metabolism have modified our understanding of the
pathophysiology of many diseases (1,2). In this regard, the detection of abnormal physiology
could help in early disease diagnosis (4,5). Early diagnosis can increase the chance of treatment
success. Glioblastoma multiforme (GBM) is one of the most aggressive gliomas and deadliest
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brain tumors, with less than half of patients surviving beyond 12–18 months even with optimal
treatment (6-9). These tumors represent the second leading cause of death among neurological
diseases in the United States and present one of the greatest challenges in the treatment of cancer
in the world (6-9).
CEST is a relatively new MRI technique that has emerged to produce contrast related to
the presence of metabolites and specific proteins. It can also be made sensitive to biological
processes such as apoptosis (10) and angiogenesis (11). However, many factors influence CEST
contrast. These factors include the concentration of the target (12), temperature (13), and pH
(14). In vivo, the pH and temperature are associated with energy producing metabolic efficiency
(14,15). Recently, many applications of CEST in cancer have focused on measuring intra- and
extra-cellular pH. Cancer is characterized by significant changes in metabolism resulting in
changes in pH that are described in detail in Section 1.2. Therefore, measuring pH is a
potentially valuable marker to indirectly probe metabolic changes in cancer.
Positron emission tomography (PET) is the current standard method to image metabolism
in cancer. Specifically, the glucose analog called 18F-labeled fluorodeoxyglucose (18F FDG) can
be detected using PET scanners, and provides a measure of glucose uptake in tumors. Measuring
tumor uptake of 18F FDG can help in the prediction of tumor response to treatment and is related
to cancer aggressiveness (16,17). Although PET has much greater detection sensitivity than
MRI, the development of metabolic imaging by MRI may have some advantages over PET
because it is easier to interpret when registered to high-resolution anatomical scans, and it is less
expensive and more accessible(18). Thus, scientists are motivated to develop novel techniques to
quantify physiological processes using MRI such as tissue acidification, to apply in cancer and
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stroke. Some metabolic imaging indicators of disease can be used to increase the accuracy of
diagnosis and prognosis compared to anatomical MR imaging (4,19).

1.2 pH Regulation in live tissue
1.2.1 Concept of the pH
The pH is a logarithmic scale that is used to measure the proton (H+) concentration of a solution.
The pH concept was first introduced by the Danish chemist Søren Peder Lauritz Sørensen at the
Carlsberg Laboratory in 1909 (20). A high concentration of protons in solution produces a low
pH value, and solutions with a low concentration of protons (H+) have a high pH value. There is
a tendency for water molecules (H2O) naturally to be ionized or dissociate into a hydroxyl ion
(OH-) and a proton (H+) according to equation (1.1).
H2O ↔ H+ +OH−

(1.1)

For example, if an aqueous solution is acidic, the [H+] is higher than [OH−] and if a solution is
alkaline, the [OH−] is higher than [H+] (21). The pH value is the negative logarithm of [H+]:
pH = −log [H+]

(1.2)

Where the [H+] is the molar concentration of protons in the solution (21).
1.2.2 pH regulation in normal tissue

Intracellular pH (pHi) is normally maintained within a narrow range by the activity of
transporters located at the plasma membrane and has an essential role in the maintenance of
normal cell function. Increases in lactate and proton concentration can cause acidification of the
tissue microenvironment in many diseases where oxygen supply is less than metabolic demand.
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The pH value is an essential marker of disease progression, as many proteins, peptides,
and macromolecules have pH-dependent structures and activities (22,23). Normal pH in both the
intra-cellular and extra-cellular compartments is maintained through the complex and
coordinated interaction between several different physiological systems including cellular
metabolism, the cellular membrane potential, intracellular and extracellular buffering systems,
cell membrane transporters, delivery of oxygen and glucose, and removal of acid by-products by
the blood (24). There are many potential pH regulators involved in this process including
Na+/HCO3– co-transporters, Na+/H+ exchangers, monocarboxylate transporters, the vacuolar
ATPase, carbonic anhydrase, anion exchangers, the Cl-/HCO3- exchangers, and ATP synthase
(25,26).
A hallmark feature of solid tumors is the maintenance of an alkaline intracellular pH
(pHi) and an acidic extracellular pH (pHe) (22,27). In normal cells, the pHe is higher (~7.4) than
the pHi of ~7.0-7.1 (24,28-32). However, the pH gradient in cancer cells is reversed, with lower
pHe (~6.7–7.1) than pHi ~7.1-7.3 (24,28-32). This altered pH homeostasis is the consequence of
increased glycolysis even in the presence of oxygen (aerobic glycolysis), known as the Warburg
effect (16). The resulting alkaline pHi benefits cancer by supporting increased cell proliferation
and evasion of apoptosis (22,33) and increases the resistance of the tumor to chemotherapy and
immunotherapy (34). Glucose metabolism plays an important role in acidification or
alkalinization of intracellular and extracellular spaces (Figure 1.1). In normal cells, glucose is
converted to pyruvate, which then enters the mitochondria and oxidized to produce CO2 and H2O
and ATP (Figure 1.1, left). In tumor cells, glucose is also converted to pyruvate, but then rapidly
converted to lactate and H+ in the cytosol (Figure 1.1, right). The transformation of glucose to
pyruvate via glycolysis occurs in the cytosol and is described in Equation (1.3).
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In the process of the breakdown of one glucose molecule, two nicotinamide adenine
dinucleotide (NAD+) molecules are reduced to form two NADH. In addition, phosphorylation of
two inorganic phosphates (Pi) and adenosine diphosphate (ADP) molecules produces two highenergy adenosine triphosphate (ATP) molecules. Two water molecules and two H+ are also
exported to the extracellular space by transporters located on the cell membrane (22,35).
Glucose + 2NAD+ + 2ADP + 2Pi →2Pyruvate + 2NADH+ 2H+ + 2ATP + 2 H2O

(1.3)

Figure 1.1 Fate of glucose in normal cell under aerobic respiration (left) and in cancer cell
under aerobic glycolysis (right).

1.2.3 pH regulation in cancer

Intracellular pH (pHi) has an important role in the maintenance of normal cell function
and is normally maintained within a narrow range by the activity of transporters located at the
plasma membrane. In cancer, changes in pHi have been correlated with both cell proliferation
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and cell death (apoptosis). In cancer tissue, the pH gradient is often reversed. Cancer cells tend to
undergo the Warburg effect which is the term given to up-regulated glycolysis under aerobic
conditions (Figure 1.1) (16,22,24,36-40).
In tumor advancement, cancer cells proliferate and compose large cellular masses, or
tumors, much faster than adequate vasculature can be produced. Cancer cells in the core of the
tumor often lack compatible circulation, and the cells that increase glycolysis tend to have an
advantage (16,22,41). Cancer cells can increase glycolysis using many control mechanisms such
as increased glucose uptake and up-regulation of pro-glycolytic enzymes such as hexokinase
(16). The result is an increased population of cancer cells favoring glycolysis. A hallmark feature
of most cancer cells is increased glucose uptake, which is commonly detected by positron
emission tomography (PET) using the uptake of the glucose analog 18F-labeled
fluorodeoxyglucose (18F FDG) (16). Therefore, cancer cells tend to have high rates of glycolysis
in both aerobic and anaerobic conditions, although anaerobic glycolysis is an inefficient
respiration pathway to produce ATP compared to the aerobic pathway. Also, cancer cells
increase the uptake of amino acids for cell proliferation. Therefore, cancer cells increase cellular
mass by relying on the Warburg effect to meet the energy demand.

A consequence of up-regulated glycolysis in cancer cells is increased amounts of
pyruvate production leading to increased proton and lactate production (16). Contradictorily,
there is a tendency for cancer cells to have an alkaline pHi compared to normal cells (22).
Although the production of lactate by cancer cells is increased, the pHi in cancer cells is more
alkaline because of increased expression of proton pumps on cellular membranes such as the
vacuolar ATPase, monocarboxylate transporters MCTs, and Na+/H+ exchangers (22,23).
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Increased expression of lactate and H+ extruders stimulates glycolysis, which is an important
energy source for proliferation and increases cancer cell survival. Also, increased efflux of H+
and lactate results in increase acidification of the extracellular microenvironment producing a
lower pHe (~ 6.7–7.1) (24,28-32). Decreased pHe provides selective advantages to cancer cells
such as increased proliferation and survival of cancer cells because the surrounding normal cells
cannot survive in the low pH extracellular space. Resultant degradation of normal cells provides
a significant advantage for evasion and tumor growth (22). Also, the alkaline pHi in cancer cells
facilitates increased cell proliferation and evasion of apoptosis (22,33) and can decrease the
efficacy of chemotherapy and immunotherapy (34). Cancer cells produce significantly more
lactate compared to normal cells (16).
Inhibition of pyruvate and lactate transporters (MCT) by drugs such as lonidamine and
quercetin impedes oxidative phosphorylation in cancer leading to energy depletion (42,43). Since
the metabolism of cancer cells is modulated by increased pHi and decreased pHe, the
measurement of pHi and pHe may improve the reliability of the diagnosis and staging of disease
advancement in tumors. Many anti-cancer agents have intracellular and extracellular pHdependent activity and pharmacokinetics. Also, the measurement of pH change has been used to
predict tumor response to chemotherapy and radiation therapy (8,25,44). Therefore pH
measurement could help to increase the efficacy of chemotherapy and improve cancer treatment
plans (24,45).
Chemotherapy agents preferentially cross the cell membrane when passing through the
acidic extracellular environment in cancer tissue. Upon entrance to the basic intracellular
space of cancer cells, the weakly acidic agents are trapped by ionization. Previous experimental
results support the use of weakly acidic chemotherapy agents when the pH balance is altered in
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cancer (24,45). In addition, tumor intracellular acidification could decrease resistance of the
tumor to weakly basic drugs such as Doxorubicin and trigger apoptosis in cancer cells (46-49).

1.3 General Overview of CEST contrast

CEST represents a relatively new class of MRI contrast that developed from the field of
NMR spectroscopy (50). Consider two separate pools of 1H nuclei in the system being measured
inside the static magnetic field (B0) of the MRI scanner. One pool is the bulk water resonating at
the Larmor frequency, the second pool is a smaller solute pool resonating at a different
frequency. A low-power radiofrequency pulse is applied at the specific MR frequency of the
solute (S) proton pool. Over time, this radiofrequency pulse will equalize the number of nuclei in
the high energy and low energy states. This condition is known as saturation of solute proton
pool. The protons are the solute pool undergo chemical exchange with protons in the bulk water
(W) pool. There is a net transfer of high energy protons to the bulk water proton pool through the
process of chemical exchange, effectively decreasing the population difference between the low
energy and high energy states. This reduces the net magnetization of the water pool leading to
decreased MR image intensity when detecting the bulk water signal. This chemical exchange
process amplifies the detected signal change caused by the low concentration solute. Using
standard MRI acquisition methods, the images can be formed from the bulk water magnetization.
To create a CEST spectrum, a radiofrequency saturation pulse is repeatedly applied over
a range of frequencies (51) (Figure 1.2). The amplitude of the bulk water signal following
application of the saturation pulse is plotted as a function of the saturation frequency (Figure
1.2). The CEST spectrum is usually referenced to the frequency of bulk water at 0 ppm. Direct
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saturation of water at 0 ppm causes a large decrease in the bulk water signal observed in the
CEST spetrum at this frequency. Importantly, the CEST effect produced by the exchange of
solute pool protons with bulk water protons causes a decrease in the bulk water signal measured
at saturation frequencies other than 0 ppm. The change in the CEST signal at these specific
frequencies is used as the measurement of the CEST effect. There are several parameters can be
used to characterize the CEST effect such as the magnitude of the change in water saturation
amplitude and the CEST peak width (52-55). The CEST spectrum corresponding to normal
mouse brain shows clear CEST peaks at 2.0 ppm and 3.5 ppm (Figure 1.3).

Figure 1.2 Basic CEST acquisition scheme (top) shows the low amplitude saturation pulse
(4s) followed by image acquisition. The acquisition is repeated for different saturation
frequencies. A series of images are produced (middle) representing the object at each
saturation frequency. A CEST spectrum is then produced (bottom) for each pixel in the
image.
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Figure 1.3 Normal mouse brain: a) coronal fast spin-echo anatomical image showing a
manually defined region of interest (sold white line), b) the CEST spectrum corresponding
to the tissue within the ROI shows visible CEST effects at 2 ppm and 3.5 ppm.

1.4 Chemical Exchange Saturation Transfer
To describe the production of CEST contrast, consider the Larmor frequency of protons
0 in a main magnetic field B0 given by Equation 1.4 where 0 is in rad s-1, B0 is in Tesla and  is
the gyromagnetic ratio in radians per second Tesla (106 rad s-1 T-1).
0 =

(1.4)
The Larmor frequency of the bulk water protons in our two pool system is set as the

reference frequency 0 for the CEST experiment. The frequency offset or chemical shift of the
solute protons () from the bulk water protons is defined in ppm according to Equation 1.5.

=

𝑠 −0
0

× 106

()

In a typical CEST experiment, solute protons resonating at a frequency that is chemically
shifted () from the bulk water protons are saturated using an RF pulse. Therefore, the
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application of an RF pulse of magnitude B1 at the frequency offset of the solute protons leads to
the excitation of protons in this pool from a lower energy state to higher energy state. The
saturation of the solute pool is achieved using RF pulses when the number of protons at each
energy level is equal. The process of chemical exchange occurs when a nucleus freely transfers
between two different pools that have environments that are chemically different. For CEST
applications and experiments, the most common pathways of chemical exchange include
molecular exchange, proton exchange, or a combination of both pathways. An example of proton
exchange is when a proton an amine group (solute pool) within a specific protein moves to the
bulk water pool (H2O). The molecular exchange is more commonly associated with CEST
contrast agents, when for example a water molecule moves from the bulk water pool to an agent
bound pool. The chemical exchange must occur on the slow-to intermediate regime on NMR
timescale to produce observable CEST contrast. This is defined by Equation 1.6.
s ≥ Ksw

(1.6)

Where s is the frequency offset between the solute and bulk water protons and Ksw
represents the chemical exchange rate from the solute to the bulk water pool. The chemical shift
is the frequency offset s normalized by the reference frequency 0. The chemical exchange
rate Ksw depends on pH and temperature for a specific sample at a fixed concentration of solute.
During a long RF saturation pulse (e.g. saturation for several seconds), through the process of
chemical exchange, protons from the solute pool will move to the bulk water pool. Since the
solute pool protons are saturated, there is a net transfer of high energy protons to the bulk water
pool causing an increase in a number of protons antiparallel with B0 (high energy protons) in this
pool (partial saturation). This reduces the net magnetization of the bulk water pool leading to a
reduction in the recorded signal. During the saturation pulse, as chemical exchange decreases
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the net magnetization of the bulk water pool (Mzw), the longitudinal relaxation of bulk water
protons restores the net magnetization. This competing process limits the achievable saturation
of the bulk water pool and over the duration of the saturation pulse leads the system to a steady
state condition. The observed CEST effect is the resulting partial saturation of the bulk water
proton pool due to saturation of the solute proton pool. The proton transfer ratio (PTR) (56) can
be used to quantify the CEST effect by measuring the reduced bulk water magnetization at
𝑠𝑠
0
steady state 𝑀𝑧𝑤
relative to the equilibrium magnetization 𝑀𝑧𝑤
as shown by:
𝑀𝑠𝑠

PTR = 1 − 𝑀𝑧𝑤
0

(1.7)

𝑧𝑤

The reduction in the bulk water MRI signal caused by the saturation of the smaller solute
pool and exchange the solute protons with bulk water protons is known as CEST contrast. CEST
acts as an amplification mechanism due to the accumulation of bulk water saturated protons over
the duration of a long RF saturation pulse.

1.4.1 The CEST Spectrum
To create a CEST spectrum (Figure 1.2) the MRI signal from bulk water at steady state
𝑠𝑠
0
𝑠𝑠
0
𝑀𝑧𝑤
is normalized to the equilibrium magnetization 𝑀𝑧𝑤
(𝑀𝑧𝑤
/𝑀𝑧𝑤
) and plotted as function of

the RF saturation pulse frequency offset (chemical shift from bulk water set to 0 ppm). The MRI
signal is obtained from a series of MR images acquired after the radiofrequency pulse is applied
at each different saturation frequency. A CEST peak can be visualized in the CEST spectrum as
a reduction in the intensity of the MRI signal if suitable experimental parameters are applied
(e.g. RF amplitude).
There are many factors that can influence CEST contrast such as: concentration of the
metabolites, pH, temperature, B0 homogeneity, B1 homogeneity, and T1 relaxation time. The
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amide-proton transfer contrast typically used to measure intracellular pH can be obtained
optimally by using a low power and long irradiation pulse. While CEST contrast from the faster
exchanging amine proton can be maximized using a higher power and a shorter irradiation pulse
(57,58).

1.4.2 Factors that Modulate CEST Contrast
One limitation of CEST imaging is the requirement of homogeneous magnetic fields (B0
and B1) to ensure consistent RF irradiation across the entire sample. Differences in B0 field
within the sample lead to shifts in the CEST spectrum. Fortunately, these shifts can be corrected
on a pixel-by-pixel basis using a separately acquired CEST spectrum and measuring the
chemical shift of the on-resonance CEST saturation of water. This water saturation shift
referencing (WASSR) approach has been used extensively (59), to account for B0 variation.
Variations in RF transmit B1 homogeneity are more difficult to correct and require careful
calibration of the CEST effect with B1 along with B1 mapping (60,61). A better approach is to
avoid the need to for correction by ensuring a homogeneous B1 field is produced within the
sample of interest. B1 mapping is required to verify that the B1 field is homogeneous and to
avoid introducing B1 corrections of the measured CEST effect.

1.5 Endogenous MRI Measurement of Intracellular pH
Although pH is an important parameter within the tissue microenvironment that impacts
numerous cellular processes and protein behavior, the measurement of in vivo intracellular pH
has been limited to only two methods: 31P MR spectroscopy and CEST.
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1.5.1

31P

The phosphorous nucleus (31P) is detectable by nuclear magnetic resonance (NMR) and is
also 100% naturally abundant. The sensitivity of 31P is 6.63% that of 1H total sensitivity because
the strength of a nuclear signal is proportional to γ³, where γ is the gyromagnetic ratio. The 31P
and the 1H have gyromagnetic ratio 17.24 MHz/T and 42.58 MHz/T respectively. Most
phosphorous containing metabolites within cells have concentrations between 0.1 mM and 10
mM. The most important NMR signals from endogenous 31P within tissues arise from inorganic
phosphate (Pi), adenosine triphosphate (ATP), and phosphocreatine (PCr). From the chemical
shift difference between the Pi and PCr peaks, the intracellular pH of mammalian tissues can be
measured accurately and non-invasively (28). The intracellular concentration of Pi is 2–3 mM,
but the extracellular concentration of Pi is only 1.0 mM. Therefore the measured chemical shift
of Pi reflects predominantly the intracellular pH of tissue. There are many cellular processes
such as necrosis that can increase the extracellular inorganic phosphate. Therefore these
processes can complicate intracellular pH measurement using 31P MRS (62).
31

P MRS has been used to study in vivo pHi for many years (28,29,32,63-68). However,

because of the low sensitivity of the 31P nucleus, to make reliable pHi measurements using 31P
MRS requires long scan times and the use of large voxels. However, the technique has been
highly valuable for monitoring changes in high-energy phosphates, Pi, and pH under hypoxic
and ischemic conditions (69-73). 31P MRS has also been used to study brain tumors (74),
showing that the intracellular pH is alkaline and not acidic as previously thought and that the
intracellular pH of tumors is higher than that of normal tissue (75).
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1.5.2 Chemical Exchange Saturation transfer (CEST)

CEST contrast has been used to measure tissue pH, based on the CEST effect observed
from amide and amine protons that resonate at chemical shifts of 3.5 ppm and 2.75 ppm
respectively downfield from bulk water [33]. The amide protons visible at 3.5 ppm are associated
with mobile proteins and peptides. Approximately 90% of proteins and peptides originate from
the intracellular compartment, and consequently, pH measured using amide and amine proton
CEST effects is heavily weighted to the intracellular space and is referred to as intracellular pH
(14,58,76,77). Intracellular pH measurement using amide proton transfer (APT) imaging was
first developed by Zhou et al. but the method proposed had several limitations [33]. They used
the asymmetric magnetization transfer ratio (MTRasym) to reduce the effect of macromolecule
magnetization transfer (MT) effects from the CEST contrast using Equation 1.8.
MTR asym () =

Mz (−)−Mz ()
Mz (−)

(1.8)

where MZ(Δω) represents the bulk water magnetization after saturation at the frequency
offset Δ and MZ(-Δω) represents the bulk water magnetization after saturation at the frequency
offset -Δ Quantitative pH measurement using APT imaging is susceptible to error because the
amide proton transfer ratio (APTR) is also affected by cellular water content, longitudinal
relaxation, and amide proton concentration. Also, nuclear Overhauser effects (NOEs), which are
observed between -2.0 and -4.0 ppm, can affect the MTRasym measurement as NOEs are directly
opposite the amide protons at 3.5 ppm. Several other CEST measurements are also sensitive to
pH. For example, amine protons associated with glutamate (58,78,79) also have exchange rates
sensitive to intracellular pH (12,80). Similarly, the hydroxyl protons associated with glucoCEST
measurements have exchange rates that are pH dependent (18,81-84). However, these hydroxyl

17

protons and the amine protons associated with glutamate are also affected by changes in
longitudinal relaxation and the concentration of protons limiting their use for measuring absolute
pH in vivo.

Another CEST based method to measure intracellular pH was developed by our group
called amine and amide concentration-independent detection (AACID). This technique uses the
ratio of the CEST effects from the 3.5 ppm amide protons and the 2.75 ppm amine protons to
produce pHi dependent contrast. Using B0-corrected (166) and smoothed CEST spectra, AACID
values were measured on a voxel-by-voxel basis. AACID represents the ratio of the CEST
effects of the amine protons resonating at 2.75 ppm and the amide protons at 3.50 ppm,
normalized by magnetization transfer (MT) effects measured after saturation at 6.0 ppm.
AACID was calculated using equation (1.9) (60).

𝐴𝐴𝐶𝐼𝐷 =

𝑀𝑍3.5 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍2.75 𝑝𝑝𝑚 )
𝑀𝑍2.75 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍3.5 𝑝𝑝𝑚 )

(1.9)

This approach was shown to be independent of tissue macromolecule concentration, tissue
temperature, and bulk water T1 relaxation (60). Importantly, the B1 amplitude of the saturation
pulse is set at an intermediate level to provide sensitivity to both amine and amide protons.
McVicar et al. (85) used AACID-CEST MRI to evaluate the sensitivity of pHi for the detection
of changes in tumor pHi induced by a single dose of lonidamine (LND) the monocarboxylate
transport inhibitor. Similarly, Marathe et al. (86) demonstrated that a single dose of topiramate, a
carbonic anhydrase inhibitor, could induce intracellular acidification in GBM tumors. The focus
of this thesis is to identify and evaluate drugs that could inhibit other pHi-regulators and
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glycolytic enzymes that modulate pHi since pH modulation by a single agent will likely be
compensated by other mechanisms over time.

1.6 Endogenous MRI Measurement of Intracellular pH in Cancer

The measurements of intracellular pH changes have been used to evaluate tumor response
to treatments such as chemotherapy and radiation therapy (25,44,87). An initial study using 31P
measurement of intracellular pH in brain tumors (74) showed that the intracellular pH of the
tumor was alkaline, not acidic. In a different study, it was also found that the intracellular pH of
untreated tumors was higher than the intracellular pH of normal tissue (75). Ben-Yoseph et al.
also used 31P MRS to measure tumor pHi after drug treatment and found a decreased of 0.45 pH
units after injection of 100 mg/kg lonidamine (87). Unfortunately, as described earlier, there are
many limitations associated with the use of 31P to measure pHi. Therefore, work in our laboratory
has focused on the use of a CEST technique called AACID to quantify the rapid and measurable
in vivo tumor acidification after drug injection (85,86,88,89).

1.7 Drugs to modulate pH in cancer:

Cancer cells consume a large amount of glucose, and convert majority of glucose to
pyruvate even in the presence of oxygen, a phenomenon known as “aerobic glycolysis” or the
“Warburg Effect” (90). Although the Warburg effect leads to higher metabolic acid production,
cancer cells also adaptively increase the expression of regulators that extrude lactate and protons
that would otherwise accumulate producing a relatively alkaline pHi and consequently increased
pyruvate production in the cytoplasm compared to normal cells (91). A hallmark feature of solid
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tumors is an alkaline intracellular pH (pHi) and an acidic extracellular pH (pHe) (22,27).
Extracellular acidosis is a hallmark feature of cancer and is an important factor that drives
malignant progression and increases metastatic potential and treatment resistance (16,92-97).
The regulation of pH in the intra- and extra-cellular compartments of the tumor is a
complex integration of many processes. These pH regulators include Na+/H+ exchangers,
monocarboxylate transporters, the vacuolar ATPase, carbonic anhydrase, anion exchangers, the
Cl-/HCO3- exchangers, Na+/HCO3– co-transporters, and ATP synthase (25,26). Maintaining an
alkaline intracellular pH benefits the cancer cell making it less likely to initiate apoptosis and
enhancing cell proliferation (22,33). An alkaline intracellular pH can also increase the resistance
of cancer to chemotherapy and immunotherapy (34,40,98-100). Inhibition of pyruvate and lactate
transporters (MCT) with drugs such as lonidamine and quercetin impedes oxidative
phosphorylation in cancer leading to energy depletion (42,43,101). Since cancer cells produce
significantly more lactate compared to normal cells (16,94,102,103), the basic pH of the
intracellular compartment is maintained by moving lactate and other acid metabolites to the
extracellular space. This causes acidification of the extracellular microenvironment and
effectively reverses the intracellular / extracellular pH gradient compared to healthy cells (104109).
There are many drugs that are capable of interfering with pH regulation in cancer cells.
As mentioned above, using 31P MRS Ben-Yoseph et al. showed that injection of lonidamine at a
dose of 50 mg/kg decreased tumor pHi by 0.25 while a dose of 100 mg/kg decreased tumor pHi
by 0.45 pH units (87). Using AACID-CEST MRI our group also found that a single dose of
lonidamine (100 mg/kg) decreased tumor pHi by 0.45 (85), and that a single dose of topiramate
(120 mg/kg) decreased pH by 0.17 (86). The objective of this thesis was to explore the
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intracellular acidification efficacy of other drugs and drug combinations. It is important to
identify additional drugs that could inhibit other regulators of pHi to modulate pHi since the
effect of a single pharmacologic agent that modulates intracellular pH will likely be compensated
by other mechanisms over time. In the following paragraphs, a number of different potential
drugs are described that target the most common pH regulatory mechanisms in cancer cells. In
all cases, the drugs described are approved for use in humans.
Na+/H+ exchange inhibitors (e.g. NHE1) play a significant role in maintaining the acidic
pHe and alkaline pHi in malignant tumors, and regulating cell volume (110). Amiloride and
cariporide are Na+/H+ exchange inhibitors. They have been used to decrease intracellular pH in
glioblastoma cells in vitro. Amiloride was able to reduce intracellular pH in U87 GBM cells
from 7.37 to 7.05 within 50 min (111). Also, cariporide decreased pHi by 0.3-0.5 pH units within
2 hours in glioblastoma cells when measured by BCECF, AM (2',7'-Bis-(2-Carboxyethyl)-5(and-6)-Carboxyfluorescein, Acetoxymethyl Ester) in vitro (111).
Quercetin is a natural plant product that has been used as an effective chemotherapeutic
agent to treat many cancer types such as breast cancer and brain cancer. Quercetin can be given
orally and is safe over a wide range of doses (94,112,113). Quercetin is an inhibitor of
monocarboxylate transporters (MCTs) (94,114-117), and has also been characterized as an
MCT1 and MCT2 specific inhibitor (114). Quercetin produces intracellular acidification in
tumors by inhibiting lactate transport (94,114-117). In addition, quercetin enhances the
efficiency of chemotherapy, suppresses human glioblastoma cell survival by increasing caspase3 activation, and induces cell apoptosis in glioblastoma and many other types of cancer cells in
vitro (118-124). Quercetin is more potent and effective in an acidic tumor microenvironment
(125-127).
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Acetazolamide induces intracellular acidification by inhibiting carbonic anhydrase
activity and decreasing the expression of the aquaporin-1 (AQP1) (128-136) water channel.
Acetazolamide has also been shown to inhibit angiogenesis and endothelial cell proliferation in
lung and breast tumor in animal models and human glioblastoma cells (137-140).
Pantoprazole (PPZ) is a proton pump inhibitor (PPI) and induces cancer cell death by
inhibiting the V-ATPase. PPIs are considered to have anti-tumor effects due to their ability to
induce tumor cell death by reversing H+ homeostasis in the tumor microenvironment by
inhibiting the V-ATPase. Pantoprazole has also been shown to be a cancer agent and is effective
against many types of cancer cells (141). PPZ can be given alone or concurrent with
chemotherapy such as doxorubicin. After PPZ treatment, apoptotic cell death was observed
selectively in cancer cells (142,143). Several PPIs (omeprazole, esomeprazole, and pantoprazole)
raise lysosomal pH and decrease intracellular pH, a feature associated with their ability to
sensitize cancer cells to chemotherapeutics (105). Agents that alter tumor pH homeostasis can
decrease drug resistance and inhibit tumor growth (99,144-153).
Dichloroacetate (DCA) is an anti cancer agent. DCA can decrease the expression of
monocarboxylate transporters and V-ATPases. It was used as a cancer treatment in two human
hepatoma (HCC-LM3 and SMMC-7721) cell lines (154). In addition, DCA has been shown to
induce cell death in cancer cell lines including from breast, prostate, lung, medullary thyroid, and
endometrial cancers, as well as myeloma and glioblastoma multiforme (47,154,155).
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Figure 1.4 pH control systems in cancer and normal cells. intracellular alkalinisation is a key
factor in cancer cells for cells transformation. pH-gradient is reversed in cancer cells
compared to the normal cells. Na+/H+, MCT (monocarboxylate transporter), CA (carbonic
anhydrase) and V-ATPase (vacuolar-ATPase) are the most important transporters and the
exchangers that cause intracellular alkalinisation of the cancer cells.
1.8 Thesis Overview:
Cancer cells have evolved a high dependence on glycolysis due to the Warburg effect.
The overall goal of this thesis is to determine whether different drugs that block various pH
regulatory mechanisms can acidify brain tumors and to measure the magnitude of tumor
acidification using CEST MRI. In this thesis, specific drugs are used to induce intracellular
acidification (lowering pHi) in brain tumors in an attempt to induce a measurable physiologic
response. The response of the tumor to each drug could be used to stage the cancer, define the
boundary of the tumor, or predict treatment response. The effect of the drug on tumor pH is
measured by CEST MRI in vivo using a mouse model of brain cancer. Chapter 2 describes the
results obtained when using the drug dichloroacetate (DCA), which is approved for human use,
to induce intracellular acidification in glioblastoma. This study is the first to show decreased
intracellular pH after DCA injection. In chapter 3, the drug cariporide is used to decrease
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intracellular pH in a mouse model of glioblastoma. Cariporide is a Na+/H+ exchange inhibitor.
Chapter 4, we tested the hypothesis that combined treatment with five drugs that block different
pH regulatory mechanisms have a greater effect on tumor acidification than any single drug. We
also tested the hypothesis that providing glucose as an energy substrate to the tumor would
increase the intracellular acidification. The final chapter of the thesis, summarizes all results
obtained and provides a framework to translate this work into humans and to continue further
testing of tumor acidification as a treatment strategy, optimized using CEST MRI.
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Chapter 2
2 Dichloroacetate Induced Intracellular Acidification in
Glioblastoma: In Vivo Detection Using AACID-CEST
MRI at 9.4 Tesla
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Abstract:
Intracellular pH (pHi) plays an important role in the maintenance of normal cell function, and is
maintained within a narrow range by the activity of transporters located at the plasma membrane.
Modulation of tumor pHi may influence proliferation, apoptosis, chemotherapy resistance, and
thermosensitivity. Chemical exchange saturation transfer (CEST) is a novel MRI contrast
mechanism that is dependent on cellular pH. Amine and amide concentration-independent
detection (AACID) is a recently developed CEST contrast method that is intracellular pH (pHi)
weighted. Dichloroacetate (DCA) can alter tumor pHi by inhibiting the enzyme pyruvate
dehydrogenase kinase causing reduced lactate (increasing pHi), or by decreasing the expression
of monocarboxylate transporters and vacuolar ATPase leading to reduced pHi. Since the net in
vivo effect of DCA on pHi is difficult to predict, the purpose of this study was to quantify the
magnitude of acute pHi change in glioblastoma after a single DCA injection using AACID CEST
MRI. Using a 9.4T MRI scanner, CEST spectra were acquired in six mice approximately 14 days
after implanting 105 U87 human glioblastoma multiforme (GBM) cells in the brain, before and
after intravenous injection of DCA (dose: 200 mg/kg). Three additional mice received only
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phosphate buffered saline (PBS) injection and were studied as controls. Repeated measures t-test
was used to compare AACID changes in tumor and contralateral tissue regions of interest. One
hour after DCA injection there was a significant increase in tumor AACID level by 0.04±0.01
corresponding to a 0.16 decrease in pHi, and no change in AACID in contralateral tissue.
Inspection of AACID maps following PBS injection showed no differences. The use of DCA to
induce a tumor specific pH change detectable by AACID CEST MRI is consistent with previous
studies that have shown similar effects for lonidamine and topiramate. This study demonstrates
that a single dose of DCA can be used as a pharmacological challenge to induced rapid tumor
intracellular acidification.
2.1 Introduction
Gliomas are the most common primary brain tumors of the central nervous system (CNS).
Glioblastoma multiforme (GBM) is one of the most aggressive gliomas and deadliest brain
tumors, with less than half of patients surviving beyond 12-18 months even with optimal
treatment (6-8,156). These tumors represent the second leading cause of death among
neurological diseases in the United States and present one of the greatest challenges in the
treatment of cancer in the world (6-9). The current standard of care of GBM tumors includes
surgical resection of the primary tumor followed by aggressive concurrent radiation and
chemotherapy (157). However, over 90% of GBM tumors recur due to migratory cancer cells
that avoid treatment (9).

In normal cells, the extracellular pH (pHe) is ~7.4, which is higher than the intracellular
pH (pHi) of ~ 7.0-7.1 (24,28-32) . A emerging hallmark feature of malignant solid tumors is
deregulation of energy metabolism (90) producing an alkaline pHi and acidic pHe; the
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intracellular/extracellular pH gradient in cancer cells is reversed such that the pHe is ~6.7–7.1
and pHi is ~ 7.1-7.3 (24,28-32). This pH gradient reversal is primarily due to the use of aerobic
glycolysis by cancer cells for energy production even in the presence of oxygen, known as the
Warburg effect (16). Although the Warburg effect leads to higher metabolic acid production,
cancer cells also adaptively increase the expression of regulators that extrude lactate and protons
producing a relatively alkaline pHi (91). These regulators include Na+/HCO3– co-transporters,
Na+/H+ exchangers, monocarboxylate transporters, the vacuolar ATPase, and carbonic
anhydrases (25,26). Increased pHi in cancer promotes proliferation and evasion of apoptosis (22).
Conversely, decreasing pHi in cell culture models has been shown to enhance the effectiveness
of hyperthermia, radiation, and chemotherapy treatments in a variety of cancer cell lines
(26,33,48,49,158).

However, the response of tumor cell cultures does not necessarily predict the behavior of
solid tumors in vivo. Until recently, the study of in vivo intracellular pH was performed by
phosphorus (31P) magnetic resonance spectroscopy (63). However,

31

P MRS measurements are

limited by low sensitivity, requiring the use of large voxels and/or long scan times to make
reliable pHi measurements. More recently, the use of endogenous chemical exchange saturation
transfer (CEST) magnetic resonance imaging (MRI) has been shown to be sensitive to
intracellular pH (58,60). One specific CEST based method called amine and amide
concentration-independent detection (AACID) uses the ratio of CEST effects from the 3.5 ppm
amide protons and the 2.75 ppm amine protons to produce pHi dependent contrast that is
independent of tissue macromolecule concentration, tissue temperature, and bulk water T1
relaxation (60). The CEST contrast originates from exchangeable amine and amide protons that
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are found in tissue proteins and peptides (14,58,77,159).

However the AACID CEST

measurement of tissue pH is highly weighted to the intracellular compartment (14) because
almost 90% of total protein content exists in the intracellular space (77). McVicar et. al. (85),
used AACID-CEST MRI to evaluate the sensitivity of pHi-dependent CEST contrast for the
detection of changes in tumor pHi induced by a single dose of the monocarboxylate transport
inhibitor lonidamine (LND). Similarly, Marathe et. al. (86) demonstrated GBM specific
intracellular acidification following a single dose of the carbonic anhydrase inhibitor topiramate.
Dichloroacetate (DCA) is a small molecule that is orally available for use in humans
(160,161), has low toxicity compared to other agents (155), and has been shown to induce cell
death in several different types of cancer (160,161).

Preclinical work using DCA shows

effectiveness as a cancer treatment to induce cell death in different types of tumors. For
example, it was used as a cancer treatment in two human hepatoma (HCC-LM3 and SMMC7721) cell lines (154). In addition, DCA induces cell death in cancer cell lines from breast,
prostate, lung, medullary thyroid, and endometrial cancers, as well as myeloma and glioblastoma
multiforme (47,154,155). However there are no ongoing clinical trials involving the use of DCA
to treat glioblastoma (clinicaltrials.gov). The effect of DCA on intracellular pH is difficult to
predict. DCA inhibits pyruvate dehydrogenase kinases (PDKs), which reverses the Warburg
effect by activating pyruvate dehydrogenase (PDH) and redirecting pyruvate back into the
mitochondria (160,162). This metabolic change is expected to increase intracellular pH by
reducing the production of lactate. However, cancer cells also have a higher expression of
monocarboxylate transporters and V-ATPases compared to normal cells. Since DCA acts to
decrease the expression of these transporters (163) it is expected to have a more pronounced
effect in cancer cells compared to normal cells leading to reduced pHi in tumors. Therefore, it is
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unclear whether a single dose of DCA would cause a net increase or decrease in pH i. The goal of
the current study was to measure the magnitude of GBM tumor intracellular pH change induced
by a single dose of DCA. The change in pHi was measured by AACID CEST MRI. We
hypothesize that a single dose of DCA will not alter pHi within contralateral tissue, but will cause
intracellular acidification within tumor regions within one hour of treatment because the effect of
DCA on MCTs and V-ATPases dominates. The combination of DCA treatment and CEST MR
imaging may provide a novel method to detect GBM tumors. The targeting of tumor metabolism
is also potentially a cancer treatment strategy (47,160) and could change the tumor
microenvironment to enhance concurrent anti-cancer treatment.
2.2 Experimental
2.2.1 Subjects
Nine mice were included in the current study. Six NU/NU mice with U87MG brain tumors were
used to evaluate the effect of injecting 200 mg/kg of DCA. Three NU/NU mice with U87MG
brain tumors were used as control. Control mice received intravenous phosphate buffered saline
(PBS) injection only. All animal procedures were performed according to a protocol that was
consistent with guidelines established by the Canadian Council on Animal Care and was
approved by the University of Western Ontario Animal Use Subcommittee.
2.2.2 Dichloroacetate
Sodium dichloroacetate (DCA) with linear formula (Cl2CHCO2Na) was purchased from Sigma –
Aldrich (Canada). The drug was dissolved in PBS (30 mg/mL). DCA was administered
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intravenously through a tail vein catheter to achieve a dose of 200 mg/kg over the course of 1
min as previously described (46,164).
2.2.3 Animal tumor preparation
GBM brain tumors were induced in 22-27g, NU/NU mice (N=6) using U87MG glioma cells
established from a human GBM (ATCC; Rockville, MD, USA) as described previously
(165). Briefly, U87MG cells were grown in Dulbecco’s modified Eagles’s medium
supplemented with 10% fetal bovine serum (Wisent Inc., St-Jean-Baptiste, QC, Canada) at 37oC
in a humidified incubator with 5% CO2 and passaged twice a week. On the day of injection,
U87MG cells were washed and dissociated with versene solution (phosphate-buffered saline
(PBS) plus 0.5 mM EDTA), then washed twice with PBS, counted and re-suspended to a final
concentration of 1 x 105 cells in 2 μl PBS. Prior to injection, mice were anesthetized by
inhalation of 4% isoflurane and maintained using 1.5% isoflurane mixed with 100% oxygen. The
mouse was placed in a stereotactic head frame (Stoelting instruments, Wood Dale, IL,
USA). The scalp was swabbed with betadine and an incision was made in the scalp to expose
the bregma. A 1 mm diameter hole was drilled at coordinates measured from the bregma (1 mm
anterior and 2 mm lateral). U87MG cells (2 μl) were injected at a rate of 0.5 l/min, at a position
3 mm deep from the bregma into the right frontal lobe using a Hamilton (Reno, NV, USA)
syringe with a 27-gauge needle attached.
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2.2.4 General mouse preparation for in vivo imaging
Approximately 15 ±1 days after cancer cell injection, the mice were scanned on a 9.4 T small
animal MRI equipped with a 30 mm millipede volume coil (Agilent, Santa Clara, CA, USA).
Anesthesia was induced using 4% isoflurane in oxygen and maintained with 1.5%–2.5%
isoflurane in 100% oxygen. The mouse was secured on a custom-built MRI-compatible stage and
the head was secured using a bite bar (86) and surgical tape to limit motion due to respiration.
Temperature was monitored with a rectal temperature probe. Body temperature was maintained
at 36.9-37.1oC throughout imaging by blowing warm air over the animal using a model 1025
small-animal monitoring and gating system (SA Instruments Inc., Stony Brook, NY, USA). To
ensure animals were free breathing throughout the study, respiration was also monitored with a
respiratory sensor pad connected to a pressure transducer that was placed on the thoracic region.
Following pre-injection imaging, the mouse was injected with DCA inside the MRI by delivering
the drug through a fine plastic tube ended with a needle inserted into the animal tail vein.
Animals were sacrificed immediately after MR imaging.
2.2.5 In vivo Magnetic Resonance Imaging
Standard anatomical T2-weighted images were used for tumor detection. The T2-weighted
images were acquired using a 2-dimensional coronal fast spin echo pulse sequence (FSE) with
parameters: TR/TE = 3000/10 ms, ETL = 4, effective TE = 40 ms, FOV = 25.6 x 25.6 mm2,
matrix size = 128 x 128, slice thickness= 1 mm, acquisition time ≈ 3 minutes. Following initial
tumor detection, the two slices from the T2-weighted images with the greatest tumor coverage
(representing a total thickness of 2 mm) were selected and the coordinates used to position the
coronal CEST image. CEST images were acquired using a fast spin-echo (FSE) pulse sequence
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(TR/TE = 7000/7 ms, ETL = 32, effective TE = 7 ms, FOV = 25.6 x 25.6 mm2, matrix size = 64
x 64, slice thickness = 2 mm, acquisition time ≈ 18 minutes) preceded by a continuous wave
radiofrequency (RF) pulse with amplitude 1.5-µT and 4s duration. The CEST images were
acquired at different saturation frequencies (from 1.2 to 4.5 (∆=0.1) ppm, from 5.4 to 6.6 (∆=0.1)
ppm, and -1000 and 1000 ppm images were acquired as references, total 49 images). A complete
series of CEST images were acquired three times before and three times after drug injection to
improve signal-to-noise ratio. For B0 correction, the water saturation shift referencing (WASSR)
technique was used (166). A linearly spaced 37-point WASSR CEST spectrum (acquisition time
≈ 9 minutes) with saturation frequencies ranging from -0.6 – 0.6 ppm was acquired using the
same pulse sequence except preceded by a short (100 ms) low amplitude (0.2 µT) RF saturation
pulse. Each WASSR spectrum (166) and CEST spectrum was interpolated to achieve 1-Hz
resolution. Each CEST spectrum was then frequency shifted, using the corresponding WASSR
spectrum (166), to account for B0 variation. B0 variations were corrected on a pixel-by-pixel
basis. The three pre- and three post-injection CEST spectra were summed following B0
corrections to increase signal to noise ratio. A B1 field map was generated using an actual flipangle imaging (AFI) pulse sequence (TR = 20 ms, TE = 3.47 ms, echoes = 2, flip-angle = 70°,
FOV = 25.6 x 25.6 mm2, matrix size= 64 x 64) in a subset of mice (N=3) to verify that the B1
variation was similar to that found in previous studies using the same experimental setup. The B1
variation in the CEST slice was less than 5%, so no B1 correction was necessary (85).
2.2.6 CEST data processing
All acquired CEST MR data were loaded into MATLAB (Mathworks, Natick, MA, USA) for
analysis. Using custom MATLAB programs previously described (85,86), B0 corrections were
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performed on a pixel-by-pixel (86) basis and all CEST spectra were smoothed using the ‘smooth’
algorithm from the MATLAB curve fitting toolbox.

2.2.7 CEST and contrast calculations
Using B0-corrected (166) and smoothed CEST spectra, AACID values were measured on a
voxel-by-voxel basis. AACID represents the ratio of the CEST effects of the amine protons
resonating at 2.75 ppm and the amide protons at 3.50 ppm, normalized by magnetization transfer
(MT) effects measured after saturation at 6.0 ppm. AACID was calculated using equation (1)
(60).

𝐴𝐴𝐶𝐼𝐷 =

𝑀𝑍3.5 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍2.75 𝑝𝑝𝑚 )
𝑀𝑍2.75 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍3.5 𝑝𝑝𝑚 )

(1)

The change in pH following drug administration was obtained using the calibration provided by
Equation (8) in McVicar et. al.
∆𝑝𝐻 = −4 × ∆𝐴𝐴𝐶𝐼𝐷

(2)

2.2.8 Statistical Analysis
Average AACID values were calculated before and after injection of DCA as well as before and
after injection of PBS, within contralateral tissue and tumor regions of interest (ROIs) defined in
each mouse brain using MATLAB (‘roipoly’ function). The ROI was drawn manually around the
tumor using the hyperintense tissue region observed in the T2-weighted images (Figures 2.1 and
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2.2) as a guide. The ROI on the contralateral side was also drawn manually to be similar in size
to the ROI used for each tumor and was positioned to mirror the location of the tumor in the
opposite hemisphere. A paired t-test was used to calculate differences in mean AACID values
measured in the tumor and in contralateral ROIs before and after injection of DCA or PBS
(control).
2.3 Results
AACID CEST maps were successfully acquired in all animals. Anatomical FSE MR images
acquired 15 ±1 days after U87MG cancer cell implantation were used to identify regions of
interest in the tumor and on the contralateral side (Figures 2.1c and 2.2c). AACID CEST maps
showed the expected decrease in AACID value in the tumor region compared to the surrounding
tissue (Figures 2.1a and 2.2a) indicating a relatively basic intracellular tumor pH. Following
injection of PBS only, there was little detectable change in the AACID map (Figures 2.1b and
2.1d). In contrast, an increase in tumor AACID value is clearly visible within the tumor (Figure
2.2b) indicating intracellular acidification within 60 minutes of DCA injection (Figure 2.2d).
Pooling all data following PBS injection, no change in AACID value was observed in the tumor
or within contralateral tissue (Figure 2.3a). However, one hour after DCA injection there was an
average increase in AACID value of 0.04±0.01 (N=6, p=0.02) in the tumor region (Figure 2.1d,
2.3b), but no change in AACID value within contralateral tissue (Figure 2.3b). The measured
change in AACID value within the tumor corresponds a 0.16 decrease in intracellular pH.
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Fig 2.1 Mouse brain with GBM tumor 14 days after implantation: a) baseline AACID map
prior to PBS intravenous injection, b) the AACID map one hour post PBS intravenous
injection c) coronal fast spin-echo anatomical image shows regions of interest (ROIs) in the
tumor (dashed white line) and on the contralateral side (solid white line) and d) AACID
difference maps for the same brain post-pre PBS injection.

Fig 2.2 Mouse brain with GBM tumor 14 days after implantation: a) baseline AACID map
prior to DCA intravenous injection, b) the AACID map one hour post DCA intravenous
injection c) coronal fast spin-echo anatomical image shows regions of interest (ROIs) in the
tumor (dashed white line) and on the contralateral side (solid white line) and d) AACID
difference maps for the same brain post-pre DCA (200 mg/kg) intravenous injection.
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Fig 2.3 Average AACID values in tumor and contralateral ROIs: a) pre and post
intravenous PBS injection as control (N=3). b) pre and post DCA 200 mg/kg intravenous
injection (N=6). Error bars represent the standard error of the mean. The asterisks indicated
p<0.05 in repeated measures t-test.

Tables
Table 2.1: AACID Values Following DCA Injection:

DCA injection 200 mg/kg
Mouse
No.
1
2
3
4
5
6

AACID Pre
Contralateral
1.229
1.327
1.314
1.348
1.266
1.273

STD
Pre
0.029
0.010
0.011
0.023
0.023
0.017

AACID Post
Contralateral
1.242
1.334
1.344
1.320
1.218
1.263

STD
Post
0.013
0.013
0.011
0.011
0.016
0.010

AACID Pre
Tumor
1.079
1.205
1.198
1.157
1.212
1.127

STD
Pre
0.018
0.011
0.013
0.008
0.015
0.013

AACID Post
Tumor
1.096
1.246
1.266
1.205
1.195
1.212

STD
Post
0.020
0.010
0.011
0.006
0.018
0.016

Average

1.292

0.019

1.287

0.012

1.163

0.013

1.203

0.013
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Table 2.2: AACID Values Following PBS Injection:

PBS injection
Mouse
1

AACID Pre
Contralateral
1.303

STD
Pre
0.006

AACID Post
Contralateral
1.246

STD
Post
0.006

AACID Pre
Tumor
1.144

STD
Pre
0.018

AACID
Post Tumor
1.140

STD
Post
0.015

2

1.280

0.006

1.280

0.008

1.239

0.011

1.205

0.007

3

1.344

0.018

1.365

0.018

1.147

0.015

1.181

0.012

Average

1.309

0.011

1.297

0.011

1.176

0.014

1.175

0.011

2.4 Discussion
This study demonstrates a tumor selective increase in the AACID CEST MRI signal suggesting
intracellular acidification in a GBM mouse brain tumor model during the first hour after
intravenous injection of a single dose of DCA (200 mg/kg). The AACID CEST MRI signal
change was estimated to be the result of a ~0.16 pH decrease based on previous calibrations. In
contrast, there was no change in the AACID CEST MRI signal on the contralateral side after
DCA injection, or within tumors or contralateral tissue following PBS injection. DCA is
approved for human consumption, is generally well tolerated (160), and has been tested as
treatment in a variety of cancers including glioblastoma (167).
DCA is an anticancer agent that alters metabolism and pHi (161,168). Previous studies
have suggested that intracellular pH may increase in cancer cells following DCA treatment as a
direct consequence of the downregulation of glycolysis by DCA (161,168). Specifically, an
increase in intracellular pH is possible because DCA is expected to increase glucose oxidation
and therefore decrease the production of lactic acid within the tumor (161,168). However, the
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current in vivo study contradicts these previous in-vitro studies. One potential explanation for
these unexpected results is that DCA has also been shown to decrease the expression of
monocarboxylate transporters and V-ATPases in tumor cells but not in normal cells (163).
Cancer cells also have a higher expression of monocarboxylate transporters and V-ATPases
compared to normal cells. Since DCA acts to decrease the expression of these transporters it is
expected to have a more pronounced effect in cancer cells compared to normal cells.
The contribution of amide, amine, and aliphatic signals to different tissue types and
cancers is an area of active research (169). The use of CEST MRI contrast to monitor
intracellular pH has many potential applications in cancer detection and treatment optimization
including the differentiation of recurrent glioma from radiation necrosis (14). The AACID CEST
measurement of tissue pH used in the current study has been shown to be independent of protein
concentration, tissue T1 relaxation, and temperature (60). Although the absolute value of
intracellular pH measurement in tumors with AACID remains to be verified, in the current study,
AACID was used to measure acute pH change following pharmacologic challenge. The AACID
CEST measurement of tissue pH used in the current study incorporates contributions from the
extracellular and intracellular compartments but is predominantly weighted to the intracellular
space due to the distribution of amine and amide protons. The paradigm of using a drug
designed to manipulate intracellular pH monitored by AACID CEST MRI is akin to
pharmacologic MRI using the blood oxygen level dependent (BOLD) contrast (170). Such
methods have several potential advantages over conventional gadolinium based contrast agents.
First, the contrast produced is based not simply on accumulation of a contrast agent, but rather is
related directly to the physiology of the tissue, or tumor. Second, use of different drugs
approved in humans provides an opportunity to test the effect of blocking different biological
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mechanisms of pH control. Different cancers may respond differently to each drug. Finally,
gadolinium-based contrast agents have the potential for side effects that are different from those
produced by drugs like DCA and must be used with caution in patients with kidney disease.
Gadolinium is also expensive compared to drugs such as DCA. The physiological information
obtained from measurement of intracellular pH changes may also provide information regarding
the response of a tumor to specific a treatment. This idea is supported by Sagiyama et. al. (8)
who found that amide proton CEST could detect temozolomide treatment effects one week after
treatment.

In previous studies using the same methodology to evaluate the magnitude of tumor
acidification we found that lonidamine, a lactate transport inhibitor, decreased intracellular tumor
pH by 0.25 (dose: 50 mg/kg), and by 0.45 (dose: 100 mg/kg) (85). In addition, topiramate, a
carbonic anhydrase inhibitor, decreased intracellular pH by 0.17 (86) at a dose of 120 mg/kg.
Topiramate is approved for use in humans as an anti-seizure medication, but lonidamine is not
currently approved in humans. At the dose used in the current study (200 mg/kg), DCA was not
as effective as lonidamine but was similar to topiramate with regard to tumor acidification. The
DCA dose (200 mg/kg) studied is commonly used in the literature for animal studies (46,47).
Pharmacologic agents that maximize cancer cell acidification would provide the greatest image
contrast for pharmacological AACID CEST MRI. Modulation of tumor metabolism and acidity
also represent an interesting and emerging target for anti-cancer treatment, either alone or in
combination with other existing treatments. Drugs that interfere with tumor metabolism could
help enhance chemotherapy and radiation therapy. In addition, tumor intracellular acidification
could decrease resistance of the tumor to weakly basic drugs such as Doxorubicin and trigger
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apoptosis in cancer cells (46-49). Acidification of the intracellular environment by regulation of
the intracellular pH is known to induce apoptosis in cancer cells even in a neutral extracellular
pH (pHe) (48). An acidic pHi may also be responsible for the activation of caspases in cancer
cells and induce DNA fragmentation (49). An acidic intracellular tumor environment may
significantly disturb tumor cell proliferation and growth (49).

The current study has several limitations that should be considered. First, the number of
animals used was small. However, the effect sizes are large and the ROI based pH
measurements have low variability. In addition, the test-retest design eliminates inter-subject
variation. Therefore the animal numbers used were sufficient to determine whether DCA
produced a measurable pH effect. Second, the AACID CEST MRI measurement of pH is based
on changes in amine and amide proton exchange rate. The decrease in intracellular pH detected
in the current study using the AACID CEST method could be verified in a future study using 31P
magnetic resonance spectroscopy. Third, we did not optimize the dose of DCA used in the
current study. Previous studies have used doses ranging from 25-200 mg/kg (47). The high dose
chosen in the current study was attempted to increase the likelihood that we would observe an
effect based on previous work (46,164). Future studies could consider higher doses of DCA
since limited side effects are expected after a single dose. Finally, DCA has multiple mechanisms
of action that could alter tissue pH. In the current study, we did not examine the effect of chronic
administration of DCA on tumor pH. Future studies should examine whether repeat exposures
would lead to decreased or increased tumor pHi.
In summary, we found that 200 mg/kg of DCA could induce acute (within 1h) tumor
AACID CEST MRI signal change likely resulting from intracellular acidification (corresponding
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to a pH decreases of 0.16) in a mouse model of glioblastoma. Since DCA is safe for use in
humans, further evaluation of AACID CEST MRI in glioblastoma patients could incorporate the
use of this drug to induce a measurable signal change.
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Abstract:
Glioblastoma is an aggressive brain cancer that is very difficult to treat. Clinically, it is important
to be able to distinguish aggressive from non-aggressive brain tumors. Previous studies have
shown that some drugs can induce a rapid change in intracellular pH that could help to identify
aggressive cancer. The sodium proton exchanger (NHE1) plays a significant role in maintaining
pH balance in the tumor microenvironment. Cariporide is a sodium proton exchange inhibitor.
We hypothesized that cariporide could selectively acidify brain tumors. The purpose of this study
was to determine whether amine/amide concentration independent detection (AACID) chemical
exchange saturation transfer (CEST) MRI measurement of tumor pHi could detect acidification
after cariporide injection. Using a 9.4T MRI scanner, CEST spectra were acquired in six mice
approximately 14 days after implanting 105 U87 human glioblastoma multiforme cells in the
brain, before and after administration of cariporide (dose: 6 mg/kg) by intraperitoneal injection.
Three additional mice were studied as controls and received only vehicle injection
(DMSO+PBS). Repeated measures t-test was used to examine changes in tumor and contralateral
tissue regions of interest. Two hours after cariporide injection there was a significant 0.12±0.03
increase in tumor AACID value corresponding to a 0.48 decrease in pHi, and no change in
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AACID value in contralateral tissue. A small but significant increase of 0.04±0.017 in tumor
AACID value was also observed following vehicle injection. This study demonstrates that acute
CEST MRI contrast changes indicative of intracellular acidification after administration of
cariporide could help localize glioblastoma.

3.1 Introduction
Gliomas are the most common primary brain tumors of the central nervous system
(CNS). Glioblastoma multiforme (GBM) is one of the most aggressive and deadliest gliomas.
The treatment for GBM tumors usually includes surgical resection of the primary tumor followed
by aggressive concurrent radiation and chemotherapy (6-8,171). However, these cancer cells
often migrate away from the primary tumor and avoid treatment, resulting in recurrence in more
than 90% of cases (171). Although new treatment strategies continue to be tested, people with
GBM typically survive only 12-18 months following diagnosis (7,8,171). Due to their
aggressive nature and high rate of recurrence, glioblastomas are considered to be one of the
greatest challenges in the treatment of cancer [1-4].
An emerging hallmark feature of solid tumors is the maintenance of an alkaline
intracellular pH (pHi) and an acidic extracellular pH (pHe) (22,27). In normal cells the pHe is
higher (~7.4) than the pHi of ~ 7.0-7.1 (24,28-32). However, the pH gradient in cancer cells is
reversed with lower pHe (~6.7–7.1) than pHi ~7.1-7.3 (24,28-32). This altered pH homeostasis is
the consequence of increased aerobic glycolysis even in the presence of oxygen, known as the
Warburg effect (16). To remove acid metabolites that would accumulate due to the Warburg
effect, cancer cells increase their expression of regulators that extrude H+ and lactate. However
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cancer cells overcompensate, producing a relatively alkaline pHi. There are many potential pH
regulators involved in this process including: Na+/HCO3– co-transporters, Na+/H+ exchangers,
monocarboxylate transporters, the vacuolar ATPase, carbonic anhydrase, anion exchangers, the
Cl-/HCO3- exchangers, and ATP synthase (25,26). The resulting alkaline pHi benefits the cancer
by supporting increased cell proliferation and evasion of apoptosis (22,33), and can increase the
resistance of the tumor to chemotherapy and immunotherapy (34). Acidification of the tumor
intracellular pH has the potential to decreased cell proliferation and induce apoptosis resulting in
cell death (26,158).
The purposeful modulation of tumor intracellular pH combined with measurement of the
pH change has been used to predict tumor response to chemotherapy and radiation therapy
(8,25,44). One method that is particularly well suited to monitoring tumor pHi is chemical
exchange saturation transfer (CEST) magnetic resonance imaging (MRI), which provides highresolution pH maps in a reasonable scan time (60). Using this approach, we have previously
shown that lonidamine a monocarboxylate transport inhibitor, topiramate a carbonic anhydrase
inhibitor, and dichloroacetate, which decreases the expression of monocarboxylate transporters
and V-ATPases, all selectively cause rapid and measurable in-vivo acidification of glioblastoma.
To make these measurements, we used a CEST technique called amine and amide concentrationindependent detection (AACID) that uses the ratio of CEST effects of amide ( = 3.5ppm) and
amine ( = 2.75ppm) protons to generate pHi dependent contrast independent of tissue
macromolecule concentration and temperature (60). Using AACID-CEST MRI we previously
found a single dose of lonidamine (LND) decreased tumor pHi by 0.45 (85), a single dose of
topiramate decreased pH by 0.17 (86), and a single dose of dichloroacetate decreased pH by 0.16
(88) approximately 1-1.5 hours after injection. Since pH modulation by a single pharmacologic
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agent will likely be compensated by other mechanisms over time, it is important to identify
additional drugs that could inhibit other key pHi-regulators and glycolytic enzymes to modulate
pHi.
Cariporide is an anticancer agent that alters metabolism and pHi by selectively inhibiting
the sodium proton (Na+/H+) exchange isoform 1 (NHE1) (172) with little effect on other ion
transport systems (173). NHE1 plays a significant role in maintaining the acidic pHe and alkaline
pHi in malignant tumors, and regulating cell volume (110). It is activated by growth factors and
cellular proliferation processes (174). In cancer cells, cariporide effectively inhibits NHE1 and
has been shown to suppress the invasion and migration of cancer cells (175). Cariporide has
already been tested in vitro in U87 and C6 glioma models. Cariporide was able to decrease
intracellular pH of U87 and C6 glioma cells each by 0.3 units within 120 min (111,176).
Furthermore, in a study of human tongue carcinoma cells (Tca8113) under hypoxic conditions,
treatment of cells with cariporide for 24h decreased pHi in a dose-dependent manner (175).
Cariporide has also been shown to decrease proliferation and migration of human umbilical vein
endothelial cells in vitro (177). In addition, cariporide was shown to have anti-angiogenetic
effects in vitro and in vivo (177). Specifically, cariporide decreased intracellular pH and downregulated vascular endothelial growth factor (VEGF) secretion in K562 leukemia and inhibited
K562 tumor growth reducing the density of microvessels in mice. These in vitro studies motivate
the current work to examine the in vivo effectiveness of cariporide in decreasing glioblastoma
pHi. An orthotopic U87MG mouse model of glioblastoma was used for the current work because
this model is known to recapitulate many of the physiological features of the human disease and
is ideally suited for the application of ultra high field AACID CEST MRI for pH measurement.
The purpose of this study was to quantify the in vivo acidification of glioblastoma following
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cariporide treatment by mapping tumor pHi using AACID CEST MRI. We hypothesized that
blockage of the sodium proton (Na+/H+) exchange isoform 1 (NHE1) by cariporide would
produce acute intracellular acidification detectable by AACID CEST MRI. The measurement of
single-dose drug induced acidification could help predict tumor response to treatment or
potentially provide information on tumor extent and aggressiveness.
3.2 Experimental
3.2.1 Subjects
Twelve female Crl:Nu-Foxn1Nu (NU/NU) mice (Charles River Laboratories, Canada) adult mice
were included in the current study in three groups. Six NU/NU mice with U87MG brain tumors
were used to evaluate the effect of cariporide on tumor pHi, three NU/NU mice with U87MG
brain tumors were injected with phosphate buffered saline (PBS) and dimethyl sulfoxide
(DMSO) as controls, and three NU/NU mice without tumors were used to study the effect of
cariporide on normal brain. One additional mouse with tumor was used for hematoxylin and
eosin (H&E) staining. Mice were group housed in ventilated racks on a 12h/12h light/dark cycle.
All animal procedures were performed according to a protocol that was consistent with
guidelines established by the Canadian Council on Animal Care and was approved by the
University of Western Ontario Animal Use Subcommittee.

3.2.2 Cariporide
Cariporide is a selective Na+/H+ exchange inhibitor with linear formula C12H17N3O3S. The drug
was purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA). The drug was
dissolved in DMSO and diluted with PBS (1:19). The DMSO was purchased from Sigma
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Aldrich Canada. Cariporide was administered by intraperitoneal (i.p.) injection at a dose of 6
mg/kg in 1 ml over the course of 2 minutes. Control mice with brain tumors received an i.p.
injection of PBS+DMSO only.

3.2.3 Animal model of glioblastoma
U87MG glioma cells established from a human GBM (ATCC; Rockville, MD, USA) were used
to induce GBM brain tumors in 22-27g, NU/NU mice (N=6) as described previously in detail
(86,88,165). Briefly, Dulbecco’s modified Eagles’s medium supplemented with 10% fetal
bovine serum (Wisent Inc., St-Jean-Baptiste, QC, Canada) was used to grow the U87MG cells at
37oC in a humidified incubator with 5% CO2. Cells were passaged twice a week. On the same
day as the injection into the brain, the U87MG cells were washed and dissociated with versene
solution (phosphate-buffered saline (PBS) plus 0.5 mM EDTA). Cells were then washed twice
with PBS, counted and re-suspended to achieve a final concentration of 1 x 105 cells in 2 μl PBS.
For injection of the cells, mice were anesthetized using 4% inhaled isoflurane and maintained
using 1.5% isoflurane mixed with 100% oxygen. A stereotactic head frame (Stoelting
instruments, Wood Dale, IL, USA) was used to guide injections through a hole drilled 1 mm
anterior and 2 mm lateral from the bregma. Using a Hamilton (Reno, NV, USA) syringe with a
27-gauge needle attached, U87MG cells (2 μl) were injected at a position 3 mm deep from the
bregma into the right frontal lobe at a rate of 0.5 l/min.
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3.2.4 General mouse preparation for in-vivo imaging
The mice were scanned using a 9.4 T small animal MRI system equipped with a 30 mm
millipede volume coil (Agilent, Palo Alto, CA, USA) 15 ±1 days after cancer cell injection as
previously described (86,88). Briefly, mice were anesthetized using 4% isoflurane in oxygen
and maintained during scanning with 1.5%–2.5% isoflurane in oxygen. A custom-built MRIcompatible stage and a bite bar were used to secure the head. Surgical tape was also used to limit
motion due to respiration. A respiratory sensor pad connected to a pressure transducer that was
placed on the thoracic region was used to monitor respiration rate. Warm air blown over the
animal using a model 1025 small-animal monitoring and gating system (SA Instruments Inc.,
Stony Brook, NY, USA) was used to maintain body temperature at 36.9-37.1oC throughout
imaging, monitored by a rectal probe. After the baseline pre-injection images were acquired, the
mouse was injected with cariporide inside the MRI by delivering the drug through fine plastic
tube ended with a needle positioned to achieve intraperitoneal injection. Animals were sacrificed
immediately after MR imaging.

3.2.5 In-vivo Magnetic Resonance Imaging
The tumor was initially localized using T2-weighted images. The T2-weighted images were
acquired using a 2-dimensional fast spin echo pulse sequence (FSE) with parameters: TR/TE =
3000/10 ms, echo train length (ETL) = 4, effective TE = 40 ms, FOV = 25.6 x 25.6 mm2, matrix
size = 128 x 128, slice thickness= 1 mm. Two slices from the stack of T2-weighted images were
selected to provide maximum tumor coverage (2 mm thickness) for CEST imaging. The CEST
images were acquired using the same methodology as previously used to study the effects of
lonidamine, topiramate, and dichloroacetate (85,86,88). Briefly, a fast spin-echo (FSE) pulse
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sequence was used (TR/TE = 7000/7 ms, ETL = 32, effective TE = 7 ms, FOV = 25.6 x 25.6
mm2, matrix size = 64 x 64, slice thickness = 2 mm, acquisition time ≈ 18 minutes) preceded by
a continuous wave radiofrequency (RF) pulse with amplitude 1.5-µT and 4s duration. Saturation
frequencies were varied from 1.2 to 4.5 ppm and from 5.4 to 6.6 ppm with step size of 0.1 ppm.
Images were also acquired with saturation frequencies of -1000 and 1000 ppm as references,
producing a total of 49 images. A complete series of CEST images were acquired three times
before and three times after drug injection to improve signal-to-noise ratio. The water saturation
shift referencing (WASSR) technique was used for B0 correction (166) also described previously
(85,86,88). A linearly spaced 37-point WASSR CEST spectrum (acquisition time ≈ 9 minutes)
with saturation frequencies ranging from -0.6 – 0.6 ppm was acquired using the same pulse
sequence except using a short (100 ms) low amplitude (0.2 µT) RF saturation pulse. Each
WASSR spectrum (166) and CEST spectrum was interpolated to achieve a 1-Hz resolution.
Each CEST spectrum was then frequency shifted, using the corresponding WASSR spectrum
(166), to account for B0 variation. B0 variations were corrected on a pixel-by-pixel basis.
Following B0 corrections the three pre- and three post-injection CEST spectra were summed to
increase signal to noise ratio.

3.2.6 CEST data processing
All CEST image processing was performed on a pixel-by-pixel basis using custom MATLAB
(Mathworks, Natick, MA, USA) code. All CEST spectra were smoothed using the ‘smooth’
algorithm from the MATLAB curve fitting toolbox. Each WASSR spectrum and CEST spectrum
was interpolated to a resolution of 1-Hz. Each CEST spectrum was then frequency shifted, using

49

the corresponding WASSR spectrum, to account for B0 variation. The three pre- and three postinjection CEST spectra were summed following B0 corrections to increase signal to noise ratio.

3.2.7 CEST and contrast calculations
AACID values were calculated on a pixel-by-pixel basis using the associated B0-corrected and
smoothed CEST spectra. The AACID value represents the ratio of the CEST effects of the amine
protons that resonate at 2.75 ppm and the amide protons that resonance at 3.50 ppm.
Macromolecule MT effects were minimized by measuring the CEST effect relative to the
saturation observed at 6.0 ppm. The AACID value was calculated using Equation (1) (60).

𝐴𝐴𝐶𝐼𝐷 =

𝑀𝑍3.5 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍2.75 𝑝𝑝𝑚 )
𝑀𝑍2.75 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍3.5 𝑝𝑝𝑚 )

(1)

Following drug administration, the change in pH was estimated by Equation (2) obtained using
the calibration provided by Equation 8 in McVicar et. al. (60).
∆𝑝𝐻 = −4 × ∆𝐴𝐴𝐶𝐼𝐷

(2)

3.2.8 Statistical Analysis
Regions of interest (ROIs) were manually defined within tumor tissue and contralateral tissue in
each mouse brain using MATLAB (‘roipoly’ function). The ROIs containing tumor tissue were
drawn manually based on the signal changes observed in the T2-weighted images. The ROIs
drawn on the contralateral side were chosen to be similar in size and position to the tumor ROI
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for each mouse. An average AACID value was calculated before and after injection of
cariporide or vehicle within each tissue ROI. Differences in mean AACID values measured in
the tumor and in contralateral ROIs before and after drug or vehicle injection were assessed
using a paired t-test with p<0.05 considered statistically significant. A similar comparison was
made in control mice after drug injection using the AACID values from the whole brain. For
control animals a whole brain ROI was drawn manually using the standard T2-weighted
anatomical images.
3.3 Results
Animals were scanned 15 ±1 days after U87MG cancer cell implantation. The anatomical FSE
MR images were used to visualize and draw ROIs in the tumor and on the contralateral side
(Figures 3.1a and 3.2a). The average weight of the mice at the time of imaging is 22-25g. Prior to
drug injection AACID CEST maps showed a lower AACID value in the tumor region compared
to the surrounding tissue as expected (Figures 3.1b and 3.2b) indicating a relatively basic
intracellular tumor pH. Following injection of vehicle only (PBS+DMSO), there was a small but
significant average increase (Figure 3.1c, 3.3a, 3.4a) in the AACID value within the tumor but no
significant change within contralateral tissue. The post-baseline difference image (Fig 3.3a)
shows a relatively constant change throughout the brain and tumor region. Following injection
of cariporide in PBS+DMSO, a significant increase in tumor AACID value of 0.21±0.02 (N=6,
p<0.05) is visible within the tumor (Figure 3.2c) indicating intracellular acidification within 2
hours of cariporide injection. There was no change in AACID value within contralateral tissue
(Figure 3.4b). The post-baseline difference image (Figure 3.3b) shows a larger effect (Figure
3.4b) compared to vehicle alone. The measured change in AACID value within the tumor after
cariporide injection corresponds to a 0.48 decrease in intracellular pH, estimated using Equation
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2. In further control experiments, there was no change in AACID value in normal brain
following injection of cariporide in PBS+DMSO (Figures 3.5 and 3.6).
Figure 3.7 shows H&E staining in a mouse with a typical brain tumor that demonstrates the size,
localization, and homogeneity of the tumor tissue.

Figure 3.1 Mouse brain with GBM tumor 15 ±1 days after implantation: a) coronal
fast spin-echo anatomical image showing regions of interest (ROIs) in the tumor
(dashed white line) and on the contralateral side (solid white line), b) the
corresponding baseline AACID map prior to PBS+DMSO intraperitoneal injection,
and c) the corresponding AACID map two hours post PBS+DMSO intraperitoneal
injection.
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Figure 3.2 Mouse brain with GBM tumor 15 ±1 days after implantation: a) coronal
fast spin-echo anatomical image showing regions of interest (ROIs) in the tumor
(dashed white line) and on the contralateral side (solid white line), b) the
corresponding baseline AACID map prior to cariporide injection, and c) the
corresponding AACID map two hours post cariporide (6 mg/kg) intraperitoneal
injection.

Figure 3.3 Mouse brain AACID difference maps for the same brains: a) post
PBS+DMSO injection - baseline, b) post cariporide (6 mg/kg) injection baseline. intraperitoneal injection.

Figure 3.4 Average AACID value in tumor and contralateral ROIs: a) pre and post
intraperitoneal PBS+DMSO injection as control (N=3). b) pre and post cariporide (6
mg/kg) intraperitoneal injection (N=6). Error bars represent the standard error of the
mean. The asterisks indicated p<0.05 in repeated measures t-test.
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Figure 3.5 Normal mouse brain: a) T2-weighted image b) AACID map prior to
cariporide injection c) AACID map post cariporide intraperitoneal injection.

Figure 3.6 Average AACID value in normal brain ROIs on the left side, right side
and whole brain: a) pre and post cariporide (6 mg/kg) intraperitoneal injection N=3.

Figure 3.7 H&E stained brain section from a representative mouse with U87 glioblastoma
multiforme (GBM) brain tumor. (a) Whole brain section. (b) Magnified region
corresponding to the black box in (a) showing the boundary of the tumor within the brain.
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3.4 Discussion
This study is the first to demonstrate changes in AACID CEST MRI indicative of
intracellular acidification in orthotopic U87MG brain tumors within the first two hours after i.p.
injection of a single dose of cariporide (6 mg/kg). The side contralateral to the tumor showed no
change in the AACID value after cariporide injection. It is also noteworthy that the vehicle
(PBS+DMSO) alone produced a small but measurable increase in AACID value within tumors.
Cariporide is an anticancer agent (172) that alters pHi by inhibiting the Na+/H+ exchange
isoform-1 (NHE-1). Cariporide is not expected to cross an intact blood-brain barrier (178,179),
however under ischemic conditions (178), and in cancer (180), it has been shown to enter the
affected tissue. The results of the current study are consistent with several previous reports that
have shown that the inhibition of Na+/H+ exchange using cariporide decreased intracellular pH in
human umbilical cord derived mesenchymal stem cells (hUC-MSCs) (181) as well as human
tongue carcinoma (175) and K562 leukemia cells (182).
We have previously used the same methodology to evaluate the magnitude of tumor
acidification following administration of the drugs lonidamine, topiramate, and DCA.
Lonidamine, a monocarboxylate transport inhibitor, decreased intracellular pH by 0.25 at a dose
of 50 mg/kg and decreased intracellular pH by 0.45 at a dose of 100 mg/kg (85). Topiramate, a
carbonic anhydrase inhibitor, decreased intracellular pH by 0.17 (86) at a dose of 120 mg/kg.
More recently we also showed that giving 200 mg/kg of dichloroacetate which decreases the
expression of monocarboxylate transporters and V-ATPases, decreased intracellular pH by 0.16
(88). At the dose studied in the current work, cariporide had a similar effect on intracellular pH
as 100 mg/kg lonidamine. However, cariporide has been tested in humans for cardiac
applications, but at the doses studied showed some toxicity and is not currently approved for
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humans. Further studies are needed to determine the utility of combing a pharmacologic
challenge using cariporide in combination with CEST MRI for cancer detection. It should be
noted that the modification of tumor intracellular pH is emerging as a novel target for anti-cancer
treatment. The use of drugs like cariporide to acidify tumors could enhance the effectiveness of
existing chemotherapies, and could also be used directly to reduce cancer cell proliferation and
tumor growth (183).
There are several limitations to the current work that should be considered when
interpreting the results. First, cariporide at the dose studied (6 mg/kg) cannot be dissolved in
distilled water or PBS. Therefore, it was dissolved in DMSO. DMSO alone caused a small
increase in AACID value suggesting a decrease in intracellular pH. However, this could be an
advantage for studies aimed at lowering intracellular pH, as long as the concentration of DMSO
is sufficiently small to limit any toxic effects. Second, in the current study, only one dose of
cariporide was examined. Future studies should determine whether higher doses of cariporide
could increase tumor acidification, and whether the effect is repeatable after multiple exposures.
Third, the number of animals included in the current study was small. However due to the large
change induced by the drug, more animals were not needed in this proof of principle study. It
should also be noted that the use of AACID CEST to measure absolute intracellular pH requires
further calibration. In the current study, an estimate of the change in pH induced by cariporide
was made using a previously published calibration performed in the brain under normoxic and
ischemic conditions (60).
In conclusion, we found an increase in AACID CEST MRI signal within 2 hours
following a single dose of cariporide indicating tumor acidification. The results of the current
study demonstrate that acute CEST MRI contrast changes after administration of cariporide
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could help localize brain cancer by rapidly and selectively inducing a shift in intracellular pH.
Since humans can tolerate cariporide, future studies in people with glioblastoma may be
warranted to determine whether pharmacologic modulation of tumor pH would aid in cancer
localization.
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Chapter 4
4 Brain Tumor Acidification using Drugs Simultaneously
Targeting Multiple pH Regulatory Mechanisms
Mohammed Albatany, Valeriy Ostapchenko, Susan Meakin, and Robert Bartha

Abstract:
Non-invasively distinguishing aggressive from non-aggressive brain tumors is an important
clinical challenge. Intracellular pH (pHi) regulation is essential for normal cell function and is
normally maintained within a narrow range. Cancer cells are characterized by a reversed
intracellular to extracellular pH gradient, compared to healthy cells that is maintained by several
distinct mechanisms. Previous studies have demonstrated acute pH modulation in glioblastoma
detectable by chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)
after blocking individual pH regulatory mechanisms. The purpose of the current study was to
simultaneously block five pH regulatory mechanisms while also providing glucose as an energy
substrate. We hypothesized that this approach would increase the acute pH modulation effect
allowing the identification of aggressive cancer. Using a 9.4T MRI scanner, CEST spectra were
acquired sensitive to pHi using amine / amide concentration independent detection (AACID).
Twelve mice were scanned approximately 11±1 days after implanting 105 U87 human
glioblastoma multiforme cells in the brain, before and after intraperitoneal injection of a
combination of five drugs (quercetin, cariporide, dichloroacetate, acetazolamide, and
pantoprazole) with and without glucose. Two hours after combination drug injection there was a
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significant 0.1±0.03 increase in tumor AACID corresponding to a 0.4 decrease in pHi. After
injecting the drug combination with glucose the AACID value decreased by 0.18±0.03
corresponding to a 0.72 decrease in pHi. AACID values were unchanged in contralateral tissue.
The combined drug treatment with glucose produced a large acute CEST MRI contrast indicating
tumor acidification, which could be used to help localize brain cancer and monitor tumor
response to chemotherapy.
4.1 Introduction
Glioblastoma multiforme (GBM) is a highly aggressive cancer and the most common
primary brain tumor of the central nervous system (CNS). The current standard of treatment
combines surgical resection of the primary tumor followed by concurrent radiation and
chemotherapy (6-8,171,184). However, due to the high migratory nature of GBM cancer cells,
many escape treatment leading to recurrence in 90% of GBM patients (171). As a result, GBM
patients often survive only 12-18 months following diagnosis (7,8,171). In the United States,
glioblastomas represent the second leading cause of death among neurological diseases and one
of the greatest challenges in the cure of cancer worldwide (6-8,171).
Cancer cells are characterized by a distinctive intracellular/extracellular pH gradient, that
is reversed compared to normal cells. Specifically, in cancer cells, the extracellular space is
acidic and the intracellular compartment is neutral or slightly basic (24,28-32,185). This reversal
of the pH gradient in tumors occurs because (16,186) aerobic glycolysis even in the presence of
oxygen, known as the Warburg effect (16), (186) produces a large quantity of acidic metabolites
that are exported to the extracellular space. The acidification of the extracellular tumor
microenvironment contributes to cancer cell evasion of apoptosis (22,33), drug resistance (34),
proliferation (33), and increased metastatic potential (16,22,24,36-40). Aggressive tumors often
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increase in size too quickly to develop adequate vasculature. Therefore cancer cells that favor
glycolysis tend to have an advantage (16,22,41). High glucose uptake (22,35), which is the basis
of cancer detection using the glucose analog 18F-labeled fluorodeoxyglucose (18F FDG) positron
emission tomography (PET) (16), and up-regulation of pro-glycolytic enzymes such as
hexokinase (16) can lead to further extracellular acidification.
Conversely, purposefully decreasing tumor intracellular pH can have several potential
beneficial applications for cancer patients. For example, the manipulation of tumor intracellular
pH may predict tumor response to chemotherapy and radiation therapy (8,25,44). Additionally,
decreasing intracellular pH in cancer cells may increase the efficacy of some anti-tumor
treatments (48,49), and may directly induce cancer cell apoptosis (49). Tumor acidification can
be achieved by blocking the regulators that extrude H+ and lactate, which maintain a relatively
alkaline tumor pHi. These regulators include carbonic anhydrase inhibitors, anion exchangers,
the Cl-/HCO3- exchangers, Na+/HCO3– co-transporters, Na+/H+ exchangers, monocarboxylate
transporters (MCT), and the vacuolar ATPase and ATP synthase (25,26). We have previously
shown that blocking specific regulators of pH can acidify the intracellular tumor environment
within two hours of dosing in a U87 GBM mouse model. Specifically, we found the MCT
inhibitor lonidamine decreased pHi by 0.25 at a dose of 50 mg/kg and decreased pHi by 0.45 at a
dose of 100 mg/kg (85), the carbonic anhydrase inhibitor topiramate 120 mg/kg decreased pHi by
0.17 (86), the MCT and V-ATPases inhibitor dichloroacetate (200 mg/kg) decreased pHi by 0.16
(88), the Na+/H+ exchange inhibitor cariporide (6 mg/kg) decreased pHi by 0.48 (187), and the
MCT inhibitor quercetin (200 mg/kg) decreased pHi by 0.27 (89). However, it is currently
unknown whether combining two or more drugs to simultaneously block multiple pH regulatory
mechanisms can produce greater tumor acidification.
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The purpose of the current study was to determine whether acute glioblastoma
intracellular acidification could be enhanced in-vivo in the U87 GBM mouse model using a
combined therapy that simultaneously blocked several major pH regulators, and to determine
whether cancer cell apoptosis increased following short term acidification treatment. We
hypothesize that combining five drugs targeting different pH regulatory pathways would induce
greater acidification within tumors than that previously found with only a single drug. We
further hypothesized that pre-treatment with glucose to provide additional substrate for aerobic
glycolysis in combination with the five drug acidification treatment would further increase
intracellular acidification. Finally, we hypothesized that short term acidification treatment would
increase tumor apoptosis. In all studies, intracellular pH was monitored in-vivo using amine /
amide concentration independent detection (AACID) chemical exchange saturation transfer
(CEST) magnetic resonance imaging (MRI).
4.2 EXPERIMENTAL
4.2.1 Subjects
Nineteen different female Crl:-Nu-Foxn1Nu (NU/NU) (Charles River Laboratories,
Canada) adult mice were included in the current study. Mice were group housed in ventilated
racks, on a 12h/12h light/dark cycle. All animal procedures were performed according to a
protocol that was consistent with the guidelines established by the Canadian Council on Animal
Care and was approved by the University of Western Ontario Animal Use Subcommittee.
For the assessment of the acute intracellular tumor acidification produced by the drug
combination, six NU/NU mice with U87MG brain tumors were used (Group A1). An additional
six NU/NU mice with U87MG brain tumors were used to evaluate the acute intracellular tumor
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acidification produced by the drug combination preceded by glucose administration (Group A2).
To assess apoptosis following brief continuous treatment (8 days), three groups of mice were
studied. The first group consisted of three mice from Group A1 that were treated with the fivedrug combination (Group T1). The second group was a control group of three mice with brain
tumors that received only vehicle (Group T2). The third group was also a control group of four
mice without tumors that were treated with the five-drug combination to assess the impact on
normal brain (Group T3).

4.2.2 Selection of Drugs to Block pH Regulation
Intracellular acidification can be achieved by inhibiting different regulators of intracellular pH
including vacuolar H+-ATPases (188,189), Na+/H+ exchangers (190,191), monocarboxylate
transporters (16,22,192), and carbonic anhydrases (193,194). In each case, drugs already used for
human use have been shown to inhibit these mechanisms. We designed a combination therapy to
simultaneously target these five pH regulatory mechanisms using drugs already approved for
human use including quercetin, pantoprazole (PPZ), acetazolamide, dichloroacetate (DCA), and
cariporide. Quercetin (Sigma –Aldrich, Canada) is an inhibitor of monocarboxylate transporters
(MCTs) (94,114-117) with linear formula C15H10O7. It specifically inhibits MCT1 and MCT2
(114). The quercetin dose used was 100 mg/kg every 8 hours (195). Pantoprazole (United States

Pharmacopeia, Maryland, USA) is a proton pump inhibitor (PPI) with linear formula
C16H14F2N3NaO4S·1.5H2O that targets the vacuolar H+-ATPase and has been shown to decrease
intracellular pH and increase apoptotic cell death in cancer cells (142,143). The pantoprazole dose
used was 2 mg/kg every 8 hours. Acetazolamide (Sigma –Aldrich, Canada) with linear formula
C4H6N4O3S2 inhibits carbonic anhydrase activity and decreases expression of the aquaporin-1

62

(AQP1) water channel (128-136). It may also inhibit angiogenesis and endothelial cell
proliferation in various cancers (137-140). The acetazolamide dose used was 50 mg/kg every 8
hours. Dichloroacetate (Sigma –Aldrich, Canada) with linear formula Cl2CHCO2Na inhibits
pyruvate dehydrogenase kinases (PDKs) and redirects pyruvate back into the mitochondria
(160,162), which reverses the Warburg effect by activating pyruvate dehydrogenase (PDH).

However, DCA also decreases the expression of monocarboxylate transporters MCTs and VATPase (163) in tumor cells, leading to reduced pHi in tumors. DCA has been shown to induce
cell death in several different types of cancer (47,154,155,160,161). The DCA dose used was 100
mg/kg every 8 hours. Finally, cariporide (Cayman Chemical Company, Michigan, USA) with
linear formula C12H17N3O3S selectively inhibits the Na+/H+ exchange isoform 1 (NHE1) (172)
with little effect on other ion transport systems (173) and has been shown to suppress the invasion
and migration of cancer cells (175). The cariporide dose used was 2 mg/kg every 8 hours.

4.2.3 Drug Delivery
All drugs were obtained in powder form and dissolved in dimethyl sulfoxide (DMSO). To assess the
acute effects on pH of the drug combination using CEST MRI (Groups A1 and A2), the drugs were
injected together in DMSO only without dilution. Specifically, the single injection contained drug doses
equal to that used for eight hours of treatment as described above. To assess whether glucose increased
tumor intracellular acidification using CEST MRI, glucose (Sigma –Aldrich, Canada) with linear formula
C6H12O6 was dissolved in PBS and administered by i.p. injection (Group A2) at a dose of 5 g/kg in 0.2
ml. Glucose was provided 20 mins before injection of the drug combination. For mice receiving
treatment (Groups T1 and T3), the drugs were diluted with phosphate buffered saline (PBS) at a ratio of
1:19 and administered by intraperitoneal (i.p.) injection in a total volume of 1 ml every 8 hours for eight
days. Control mice with brain tumors (Group T2) received DMSO+PBS at a ratio of 1:19 in a total
volume of 1 ml every eight hours for eight days.
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4.2.4 Animal Model of Glioblastoma
The GBM animal model has been published previously but is provided for completeness
(85,88,89,187) GBM brain tumors were induced in 22-27g, NU/NU mice (N=15) using U87MG
glioma cells established from a human GBM (ATCC; Rockville, MD, USA) as described
previously (165). Briefly, U87MG cells were grown in Dulbecco’s modified Eagles' medium
supplemented with 10% fetal bovine serum (Wisent Inc., St-Jean-Baptiste, QC, Canada) at 37 oC
in a humidified incubator with 5% CO2 and passaged twice a week. On the day of injection,
U87MG cells were washed and dissociated with versene solution (phosphate-buffered saline
(PBS) plus 0.5 mM EDTA), then washed twice with PBS, counted and re-suspended to a final
concentration of 1 x 105 cells in 2 mL PBS. Before injection, mice were anesthetized by
inhalation of 4% isoflurane and maintained using 1.5% isoflurane. The mouse was placed in a
stereotactic head frame (Stoelting instruments, Wood Dale, IL, USA). The scalp was swabbed
with betadine, and an incision was made in the scalp to expose the bregma. A 1 mm diameter
hole was drilled at coordinates measured from the bregma (1 mm anterior and 2 mm lateral).
U87MG cells (2 µl) were injected at a rate of 0.5 L/min, at a position 3 mm deep from the
bregma into the right frontal lobe using a Hamilton (Reno, NV, USA) syringe with a 27-gauge
needle attached.
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4.2.5 Mouse Preparation for In-vivo Imaging
Approximately 11±1 days after cancer cell injection, the mice in Groups A1 and A2 were
scanned on a 9.4 T small animal MRI system equipped with a 30 mm millipede volume coil
(Agilent, Palo Alto, CA, USA). Anesthesia was induced using 4% isoflurane in oxygen and
maintained with 1.5%–2.5% isoflurane in oxygen. Each mouse was secured on a custom-built
MRI-compatible stage, and the head was secured using a bite bar (86) and surgical tape to limit
motion due to respiration. Animal temperature was monitored with a rectal temperature probe,
and respiration was monitored with a respiratory sensor pad connected to a pressure transducer
that was placed on the thoracic region. Body temperature was maintained at 36.9-37.1 oC
throughout imaging by blowing warm air over the animal using a model 1025 small-animal
monitoring and gating system (SA Instruments Inc., Stony Brook, NY, USA). Following
baseline imaging, the mouse was injected with the drug combination inside the MRI through fine
plastic tube ended with a needle to deliver into the peritoneum. Following imaging, three animals
from Group A1 were treated with the five drug combination for eight days (Group T1), while all
others animals were sacrificed immediately after MR imaging.

4.2.6 In-vivo Magnetic Resonance Imaging and pH-weighted imaging
The imaging protocol used in this study has been published previously (85,88,187). Briefly, T2weighted images were used for tumor detection acquired using a 2-dimensional fast spin echo
pulse sequence (FSE) with parameters: TR/TE = 3000/10 ms, ETL = 4, effective TE = 40 ms,
FOV = 25.6 x 25.6 mm2, matrix size = 128 x 128, slice thickness= 1 mm. Two slices from the
series of T2-weighted images with maximum tumor coverage were selected for CEST imaging.
CEST images were acquired using a fast spin-echo (FSE) pulse sequence (TR/TE = 7000/7 ms,
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ETL = 32, effective TE = 7 ms, FOV = 25.6 x 25.6 mm2, matrix size = 64 x 64, slice thickness =
2 mm) preceded by a continuous wave radiofrequency (RF) pulse with amplitude 1.5-µT and 4s
duration. The CEST images were acquired at different saturation frequencies (from 1.2 to 4.5
(∆=0.1) ppm, from 5.4 to 6.6 (∆=0.1) ppm, and -1000 and 1000 ppm images were acquired as a
reference, total 49 images). A complete series of CEST images were acquired three times before
and three times after drug injection to improve the signal-to-noise ratio. For B0 correction, the
water saturation shift referencing (WASSR) technique was used (166). A linearly spaced 37point WASSR CEST spectrum with saturation frequencies ranging from -0.6 – 0.6 ppm was
acquired using the same pulse sequence except preceded by a short RF saturation pulse (100 ms)
with low amplitude (0.2µT).
4.2.7 CEST Data Processing
All acquired CEST MR data were processed on a pixel-by-pixel basis using custom MATLAB
(Mathworks, Natick, MA, USA) code for analysis as previously described (85,88,89,187). Each
WASSR spectrum and CEST spectrum was interpolated to achieve 1-Hz resolution. All CEST
spectra were smoothed using the ‘smooth’ algorithm from the MATLAB curve fitting toolbox.
Each CEST spectrum was then frequency shifted, using the corresponding WASSR spectrum, to
account for B0 variation. B0 variations were corrected on a pixel-by-pixel basis. The three preand three post-injection CEST spectra were summed following B0 corrections to increase signal
to noise ratio. As previously shown (85), the B1 variation in the CEST slice was less than 5%, so
no B1 correction was applied (85).
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4.2.8 Mapping Tissue Intracellular pH
Tissue pHi was monitored using amine and amide concentration-independent detection
(AACID), which uses the ratio of CEST effects from amide ( = 3.5ppm) and amine ( =
2.75ppm) protons to generate pHi dependent contrast independent of tissue macromolecule
concentration and temperature (60). The CEST contrast originates from exchangeable amine and
amide protons that are found in tissue proteins and peptides (14,58,77,159). However the
AACID CEST measurement of tissue pH is highly weighted to the intracellular compartment
(14) because almost 90% of total protein content exists in the intracellular space (77). AACID
values were measured on a pixel-by-pixel basis using the associated B0-corrected and smoothed
CEST spectra. The AACID value represents the ratio of the CEST effects of amine protons
resonating at 2.75 ppm and amide protons at 3.50 ppm, normalized by MT effects measured after
saturation at 6.0 ppm and is calculated using equation (1) (60).

𝐴𝐴𝐶𝐼𝐷 =

𝑀𝑍3.5 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍2.75 𝑝𝑝𝑚 )
𝑀𝑍2.75 𝑝𝑝𝑚 ×(𝑀𝑍6.0 𝑝𝑝𝑚 −𝑀𝑍3.5 𝑝𝑝𝑚 )

(1)

Following drug administration, the change in pH was estimated by Equation (2) obtained using
the calibration provided by Equation (8) in McVicar et al. (60).
∆𝑝𝐻 = −4 × ∆𝐴𝐴𝐶𝐼𝐷

(2)
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4.2.9 Immunohistochemistry on mouse brains
On day 18-19 after injection of cancer cells, mice were euthanized and perfused with 4%
paraformaldehyde in PBS as described previously (196). After 24-hour incubation in 4%
paraformaldehyde at 4 C, brains were cut using a vibratome into 80-µm coronal sections.
Randomly chosen sections containing tumor were then immunostained as described previously
(197), using an anti-cleaved caspase-3 (CC3) antibody (Cell Signaling, cat#9664, 1:500) and
Alexa Fluor 488 secondary anti-rabbit antibody (Thermo Fisher, cat#A-11008), followed by
nuclear staining with Hoechst 33342. Stained brain sections were mounted on glass slides using
Immu-mount (Thermo Scientific, cat#9990402) and imaged using a FV1000 confocal
microscope (Olympus) equipped with a 10x/0.4 or a 20x/0.75 objective. Images were stitched
using FluoView software (Olympus) and analyzed using ImageJ Measure and Cell Counter
plugins (NIH, Bethesda, MD). At least three sections per animal and at least three animals per
condition were analyzed. Apoptosis was quantified using the number of CC3-positive cells per
mm3.

4.2.10 Statistical Analysis
Regions of interest (ROIs) containing tumor tissue and contralateral tissue were drawn manually
in each mouse brain using the MATLAB (‘roipoly’ function) using the contrast observed in the
T2-weighted images as a guide. Average AACID values were calculated before and after
injection of the drug combination within each ROI. A paired t-test was used to calculate
differences in mean AACID values measured in the tumor and contralateral ROIs before and
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after injection of the drug combination and the drug combination plus glucose. The number of
CC3 positive cells per mm3 were compared between treatment groups using a Student’s t-test in
Prism (GraphPad). In all comparisons, p<0.05 was considered statistically significant.
4.3 Results
AACID CEST maps were acquired in all animals 11 ±1 days after U87MG cancer cell
implantation. Anatomical FSE MR images were successfully used to identify regions of interest
in the tumor and on the contralateral side (Figures 4.1c and 4.2c). AACID CEST maps showed
the expected lower AACID value in the tumor region compared to the surrounding brain tissue
(Figures 4.1a and 4.2a) indicating a relatively basic intracellular tumor pH. Also, as expected, a
large increase in tumor AACID value was observed within the tumor following the injection of
the drug combination (Figure 4.1b) indicating rapid intracellular acidification within 2 hours of
injection. As expected, the difference between the post and pre images in a single animal showed
a greater effect in the tumor ROI compared to the contralateral ROI (Figure 4.1d). Specifically,
two hours after injection of the drug combination, there was an average increase in the AACID
value of 0.10±0.03 (N=6, p<0.05) in the tumor region (Figure 4.3a), but no change in AACID
value within the contralateral tissue (Figure 4.3a). When providing glucose prior to the combined
drug injection an even larger increase in AACID value was visible (Figure 4.2b) suggesting even
greater acidification was achieved. When pre-treating with glucose, there was a significant
increase in the AACID value of 0.18±0.03 (N=6, p<0.0001) two hours after the combination
drug injection in the tumor region (Figure 4.3b). However, there was also a small change in the
AACID value within the contralateral tissue (Figure 4.3b). The difference between the post and
pre images in a single animal (Figure 4.2d) showed a greater effect in the tumor ROI compared
to the contralateral ROI as expected. The measured changes in the average AACID value within

69

the tumor after the combination drug treatment corresponded to a 0.4 pH drop, while
pretreatment with glucose produced a 0.72 pH drop, estimated using Equation 2.
All animals in Groups T1 and T3 completed eight days of drug treatment. Representative
immunostained brain sections showing the results of cleaved (active) caspase 3 (CC3)
immunostaining as a marker of apoptotic cell death are provided in Figure 4.4. Control mice
without tumors showed almost no evidence of CC3 staining (Figure 4.4A). However, within
tumors, CC3 staining was increased in the control group (Figure 4.4B, 4.4D) and after treatment
(Figure 4.4C, 4.4D) in the treatment group. In the mice treated with the five drug combination
there was a significant increase in CC3 levels (p=0.0023) (Figures 4.4C, 4.4D).
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Figure 4.1 Mouse brain with GBM tumor 11 ±1 days after implantation: a) baseline
AACID map prior to drug injection, b) the AACID map two hours post drug injection, c)
coronal fast spin-echo anatomical image showing the ROIs in the tumor (dashed white
line) and on the contralateral side (solid white line), and d) AACID difference maps for
the same brain post–pre drug injection.

Figure 4.2 Mouse brain with GBM tumor 11 ±1 days after implantation: a) baseline
AACID map prior to drug and glucose injections, b) the AACID map two hours post drug
and glucose injections, c) coronal fast spin-echo anatomical image showing the ROIs in the
tumor (dashed white line) and on the contralateral side (solid white line), and d) AACID
difference maps for the same brain post–pre drug and glucose injections.
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Figure 4.3 Average AACID value in tumor and contralateral ROIs: a) pre and post
intraperitoneal five drug combination injection (N=6). b) pre and post five drug
combination + glucose intraperitoneal injection (N=6). Error bars represent the
standard error of the mean. The asterisks indicated p<0.05 in repeated measures ttest.
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Figure 4.4 Cleaved Caspase 3 (CC3) Increases in Tumor after Treatment. (A-C)
Representative images of coronal brain sections of (A) non-tumor control mice, (B)
mice with U87 tumors, non-treated receiving vehicle only, and (C) mice with tumors,
treated for eight days with the five drug combination. Blue corresponds to nuclear
stain (Hoechst), red corresponds to CC3 (apoptotic marker). Scale bar: 0.4 mm. (D)
Quantification of apoptotic cells in (A-C). ** indicate p<0.01.
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4.4 Discussion
This study demonstrates intracellular acidification in brain tumors two hours after
injection of a single dose of five drugs designed to block different pH regulatory mechanisms.
Tumor acidification was further enhanced by pretreatment with glucose. The magnitude of these
changes is larger than that reported previously for single drug treatment. In contrast, there was no
change in brain tissue pH detected on the side contralateral to the tumor after combined drug
injection, but there was a small decrease in pH on the contralateral side when glucose was given
prior to the combined drug injection. Eight days of treatment with the five drug combination
significantly increased the number of cells positive for cleaved caspase 3 within the tumor.
The drug combination used in the current study was designed to block multiple pH
regulatory mechanisms to enhance the acidification produced by any single compound.
Quercetin is a natural compound, and a plant product that has been used as a chemotherapeutic
agent to treat many cancer types(116,117,198). Quercetin is an MCT inhibitor (94,114-117) that
specifically inhibits MCT1 and MCT2 (114). Pantoprazole (PPZ) has also been shown to be an
anti-cancer agent (141) due to its ability to induce cancer cell death by inhibiting the V-ATPase
causing reversal of H+ homeostasis. Acetazolamide induces intracellular acidification by
inhibiting carbonic anhydrase activity and decreasing aquaporin-1 (AQP1) water channel protein
expression (128-136). Dichloroacetate (DCA) is a small molecule and has low toxicity compared
to other anti-cancer agents (155). DCA has been shown to induce cell death in several different
types of cancer (160,161). DCA inhibits pyruvate dehydrogenase kinases (PDKs) and redirects
pyruvate back into the mitochondria (160,162), which reverses the Warburg effect by activating
pyruvate dehydrogenase (PDH). However, DCA also decreases the expression of
monocarboxylate transporters and V-ATPase (163) in cancer cells reducing pHi in tumors.
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Cariporide selectively inhibits the sodium proton (Na+/H+) exchange isoform 1 (NHE1) (172)
with little effect on other ion transport systems (173). In malignant tumors NHE1 plays a
significant role in maintaining acidic pHe, alkaline pHi, and regulating cell volume (110). It is
activated by growth factors and cellular proliferation processes (174). Cariporide effectively
inhibits NHE1 and has been shown to suppress the invasion and migration of cancer cells (175).
Cariporide also decreased intracellular pH and down-regulates vascular endothelial growth factor
(VEGF) secretion in K562 leukemia cells (182). Therefore, using these specific drugs blocks
several known pH regulatory mechanisms: Na+/H+ exchange, monocarboxylate transporters
(MCTs), carbonic anhydrase and aquaporin-1(AQP1), pyruvate dehydrogenase kinases (PDKs)
and V-ATPase.
In previous studies using the same methodology to evaluate the magnitude of tumor
acidification, we found lonidamine decreased pHi by 0.25 at a dose of 50 mg/kg and decreased
pHi by 0.45 at a dose of 100 mg/kg (85) while topiramate decreased pHi by 0.17 (86). More
recently we also showed that 200 mg/kg of dichloroacetate decreased pHi by 0.16 (88), and that 6
mg/kg of cariporide decreased pHi by 0.48 (187). At the dose studied, the combination of drugs
used in the current study decreased pHi by 0.4 alone and by 0.72 in combination with glucose.
Although the five drug combination produced a pHi change similar to that shown previously with
100 mg/kg of lonidamine and 6 mg/kg of cariporide, the combination used in the current study
used mostly drugs considered safe in humans and used a much lower dose of cariporide (one
third of that used previously) and DCA (half of that used previously). The dose was lowered in
the current study to reduce potential side effects and interactions.
In an effort to further enhance intracellular acidification, glucose was injected 20 minutes
prior to drug injection. Cancer cells readily take up and metabolize glucose more so than normal
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cells, which forms the basis of cancer detection using fluorodeoxyglucose (18F-FDG) positron
emission tomography (PET). The end products of glucose metabolism are protons and lactate,
which are normally removed from the cell by the pH regulatory mechanism targeted in this
study. Blocking these mechanisms 20 minutes after glucose injection produced a much larger
acute intracellular acidification effect. The application of several drugs together, in combination
with glucose achieved greater tumor intracellular acidification than any previous single drug
studied.
To study the long-term effect of intracellular acidification on cancer cell viability in-vivo,
the five-drug combination was given to mice three times per day for eight days. Within the
tumor, there was a significant increase in the number of cells staining positive for cleaved
caspase 3, suggesting an increase in the number of cells undergoing apoptosis. There were very
few cells undergoing apoptosis in normal brain, after being given the same drug treatment. These
in-vivo results are consistent with previous studies of cancer cell lines, which have shown that
cancer cell acidification can induce apoptosis in a variety of cancer models(149,199-203). The
results from the current study provide further evidence that tumor intracellular acidification may
provide a benefit for cancer control and treatment.
The current study has several limitations that should be considered. First, the number of
animals used was small. However, as in previous studies by our group, the effect sizes are large,
and the ROI based pH measurements have low variability. Also, the test-retest design reduces
inter-subject variation. Therefore, the animal numbers used were sufficient to determine whether
the drug combination could produce a measurable pH effect. Second, we did not optimize the
combination dose in the current study, only one dose of drugs was examined. Future studies
should determine whether higher doses of these drugs could produce a greater effect, or if a
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similar effect would be produced with lower doses, decreasing the risk of potential side effects.
It should also be established whether the effect is repeatable after multiple exposures and
whether the treatment would be more effective is started earlier on in the development of the
tumor. The timing and dose of glucose supplementation to increase cellular metabolism prior to
drug injection should be studied to optimize intracellular acidification, and consequently cancer
cell death. Future studies should also examine whether chronic intracellular acidification could
enhance the efficacy of existing chemotherapies.
The use of CEST MRI contrast to detect changes in intracellular pH has many potential clinical
applications in cancer detection and treatment evaluation (8,14,157). The results of the current
study further demonstrate that acute CEST MRI contrast changes after administration of several
drugs in combination with glucose could help localize brain cancer by rapidly and selectively
inducing a shift in intracellular pH. The current study demonstrated that the magnitude of
intracellular acidification (AACID) of the tumor after combined drug injection was larger when
providing glucose as a substrate.
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Chapter 5
5 Conclusions and Future Directions
5.1 Summary of Findings
The overall goal of the work presented in this thesis was to maximize intracellular tumor
acidification following drug treatment. In the first study, one hour after DCA intravenous
injection (200 mg/kg) there was a significant increase in tumor AACID level by 0.04±0.01
corresponding to a 0.16 decrease in pHi, and no change in AACID in contralateral tissue. In the
second study presented, two hours after cariporide intraperitoneal injection there was a
significant 0.12±0.03 increase in tumor AACID value corresponding to a 0.48 decrease in pHi,
and no change in AACID value in contralateral tissue. Finally, in the last study presented, two
hours after combination drug intraperitoneal injection there was a significant 0.10±0.03 increase
in tumor AACID corresponding to a 0.40 decrease in pHi. After injecting the drug combination
with glucose the AACID value decreased by 0.18±0.03 corresponding to a 0.72 decrease in pHi.
AACID values were unchanged in contralateral tissue. The results of the current study further
demonstrate that acute CEST MRI contrast changes after administration of several drugs in
combination with glucose could help localize brain cancer by rapidly and selectively inducing a
shift in intracellular pH. We designed a combination therapy to simultaneously target these five
pH regulatory mechanisms using drugs already approved for human use including quercetin,
pantoprazole (PPZ), acetazolamide, dichloroacetate (DCA), and cariporide. The current study
demonstrated that the magnitude of intracellular acidification (AACID) of the tumor after
combined drug injection was larger when providing glucose as a substrate.
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5.2 Limitations
There are several limitations to the current work that should be considered.
1. The number of animals used was small. However, as in previous studies by our group, the
effect sizes are large, and the ROI based pH measurements have low variability. Also, the testretest design reduces inter-subject variation. Therefore, the animal numbers used were sufficient
to determine whether the drugs could produce a measurable pH effect.
2. Cariporide and quercetin at the doses studied cannot be dissolved in distilled water or PBS.
Therefore, these drugs were dissolved in DMSO. DMSO alone caused a small increase in
AACID value suggesting a decrease in intracellular pH. This could be considered an advantage
for studies aimed at lowering intracellular pH, as long as the concentration of DMSO is
sufficiently small to limit any toxic effects.
3. We did not optimize the combination drug doses in the current study, only one dose of drugs
was examined. Future studies should determine whether higher doses of these drugs could
produce a greater effect, or if a similar effect would be produced with lower doses, decreasing
the risk of potential side effects. It should also be established whether the effect is repeatable
after multiple exposures and whether the treatment would be more effective is started earlier on
in the development of the tumor. The timing and dose of glucose supplementation to increase
cellular metabolism prior to drug injection should be studied to optimize intracellular
acidification, and consequently cancer cell death. We only studied one animal model in cancer,
also, we do not have a calibration of AACID measurement within tumors to make absolute pH
measurements. Future studies should also examine whether chronic intracellular acidification
could enhance the efficacy of existing chemotherapies.
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5.3 Conclusion
The use of CEST MRI contrast to detect changes in intracellular pH has many potential clinical
applications in cancer detection and treatment evaluation (8,14,157). The results of the current
study further demonstrate that acute CEST MRI contrast changes (86,89,187,204) after
administration of several drugs in combination with glucose could help localize brain cancer by
rapidly and selectively inducing a shift in intracellular pH. The current study demonstrated that
the magnitude of intracellular acidification (AACID) of the tumor after combined drug injection
was larger when providing glucose as a substrate could help localize brain cancer by rapidly and
selectively inducing a shift in intracellular pH. Since the drugs are approved for use in humans,
future studies in people with glioblastoma should be performed to determine whether
pharmacologic modulation of tumor pH would aid in cancer localization.

5.4 Future directions
This thesis studied the effect of the MCT and V-ATPases inhibitor dichloroacetate, Na+/H+
exchange inhibitor cariporide, and a combination therapy to simultaneously target five pH
regulatory mechanisms using mostly drugs approved for human use including quercetin,
pantoprazole (PPZ), acetazolamide, and dichloroacetate (DCA).
We did not optimize the combination dose in the current study, only one dose of drugs was
examined. Future studies should determine whether higher doses of these drugs could produce a
greater effect, or if a similar effect would be produced with lower doses, decreasing the risk of
potential side effects. It should also be established whether the effect is repeatable after multiple
exposures.
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Also, future work should evaluate the effect of these drugs on tumor pHi and determine which
combination of drugs cause the greatest decrease in pHi with therapeutic dosages. Also, to design
experiments to observe the effects of these drug combinations on tumor growth and optimize the
dose for maximum growth delay and enhancement of the efficacy of chemotherapy drugs.
Also, it is interesting to design experiments to measure pHe along with pHi (185) to monitor the
effect on extracellular-intracellular pH, as it is the pH gradient across the plasma membrane that
impacts the efficacy of chemotherapy drugs. This simultaneous measurement of pH gradient may
help to design the most effective treatment regime. Most recently, contributed to a published
study of longitudinal measurement of the intracellular/extracellular pH gradient in a rat glioma
model using MRI. pHi was mapped using CEST MRI, whereas regional pHe was determined
using hyperpolarized 13C bicarbonate magnetic resonance spectroscopic imaging at 3 Tesla
(185).
The results from this study indicate the potential value of carbonic anhydrase inhibitors in tumor
acidification and hopefully will stimulate future experiments to expand the role of such drugs in
cancer treatment.
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